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ABSTRACT 
 
 
 
   CBX7 is a member of the Polycomb Repressive Complex 1 (PRC1) involved in 
the process of human and mouse tumorigenesis. Recently, we have demonstrated 
that CBX7 is drastically decreased in several human carcinomas and that CBX7 
protein levels progressively decreased in relation with the malignant grade and the 
neoplastic stage. To characterize the mechanisms by which the loss of CBX7 
contributes to the process of carcinogenesis, we analyzed the gene expression 
profiling of an anaplastic thyroid carcinoma cell line in which the expression of 
CBX7 was restored and found that CBX7 was able to negatively or positively 
regulate the expression of several genes (such as SPP1, SPINK1, STEAP1, and 
FOS, FOSB, EGR1, respectively) associated with cancer progression. By 
quantitative (q)RT-PCR, we confirmed these data in mouse and rat system in which 
the expression of Cbx7 was silenced. Then, we showed that CBX7 was able to 
physically interact with the promoter region of these genes, thus regulating their 
activity. qRT-PCR analysis performed on thyroid and lung carcinoma samples with 
different degree of malignancy, showed a negative correlation between CBX7 and 
its down-regulated genes, while a positive correlation was observed between CBX7 
and its up-regulated genes. Recently, we have demonstrated that CBX7 protein is 
able to interact with the High Mobility Group A 1 (HMGA1) protein. Therefore, we 
asked whether this interaction could be involved in the transcriptional regulation of 
the SPP1 gene.qRT-PCR analysis demonstrated that HMGA1 protein is able to 
increase the SPP1 expression in several cellular systems. Moreover, by chromatin 
immunoprecipitation assays, we found that HMGA1 binds together with CBX7 
protein to the SPP1 promoter and that the two proteins compete for the binding. 
Finally, functional assays showed that CBX7 is able to negatively regulate cellular 
migration by repressing transcriptional activation of the SPP1promoter. 
In conclusion, the loss of CBX7 expression might play a critical role in cancer 
progression by deregulating the expression of specific effector genes. 
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1. BACKGROUND 
 
 
 
1.1 Polycomb Group proteins (PcG) 
 
   Polycomb Group (PcG) proteins are transcriptional repressors that bind to histone 
modifications, thus maintaining gene expression in a silenced state (Otte et al. 
2003,Lund and van Lohuizen 2004). PcG proteins are part of two complexes with 
high molecular weight named Polycomb Repressive Complex 1 and 2 (PRC1 and 
PRC2) (Sparmann and Van Lohuizen 2006, Schwartz and Pirrotta 2007). The 
PRC2 has associated histone deacetylase and histone methyl transferase activities 
(specific for the lysine 27 on the histone H3, K27H3me3) (Kuzmichev et al. 2002, 
Kirmizis et al. 2007) while the PRC1 recognizes and binds to the K27H3me3 
through the chromodomain of the Polycomb (Pc) proteins thus catalyzing the 
mono-ubiquitilation of the histone H2A on lysine 119 and shutting down gene 
transcription (Wang et al. 2004, Cao et al. 2005, Sparmann and van Lohuizen 
2006). However, a recent study has demonstrated that PRC1 is also able to mono-
ubiquitilate the histone H2A in a H3K27me3-independent pathwayin PRC2-
deficient mouse embryonic stem cells (mESCs) (Tavares et al. 2012). 
The components of the PRC1 in mammals are the homologs of Drosophila 
melanogaster Polycomb (Pc), Posterior sex combs (Psc), Sex combs extra (Sce) 
and Polyhomeiotic (Ph) proteins (Shao et al 1999, Saurin et al 2001). Because of 
the presence in mammalian cells of five Pc proteins (Chromobox homolog proteins, 
CBX2, CBX4, CBX6, CBX7 and CBX8), six Psc proteins (BMI1, MEL18, MBLR, 
NSPC1, RNF159, and RNF3), three Ph proteins (HPH1, HPH2 and HPH3) and two 
Sce ubiquitin ligase activity proteins (RING1a and RING1b), there is an enormous 
diversity for combinatorial association between these proteins (Gil and Peters 2006, 
Whitcomb et al. 2007). The histone lysine methyl-transferase enhancer of zeste 
homolog 2 (EZH2), embryonic ectoderm development (EED) and suppressor of 
zeste homolog 12 (SUZ12) are the known mammalian components of the PRC2 
(Figure 1.1). Mammalian PRC1 may exhibit additional contextual specifity by 
selecting one of the multiple Pc/CBX proteins. Each of every chromobox protein 
confers distinct sub-chromosomic distribution and dynamic patterns to the complex 
(Bernstein et al. 2006).  
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Figure 1.1 Polycomb Group proteins and the mechanism of transcriptional 
repression 
(A) EED, SUZ12 and EZH2 are the mammals homolog of the Drosophila melanogaster 
components of the PRC2 reported in the red box.(B) The binding of the PRC2 to the 
Polycomb responsive elements (PREs) promotes methylation of the histone H3 on the 
lysine 27 (H3K27), mediated by EZH2, around the PREs in the promoter of the silenced 
genes. (C) In mammals there is enormous diversity for combinatorial association of PRC1 
members due to the presence of many homolog of these Drosophila melanogaster 
proteins. (D) The PRC1 recognizes and binds to the H3K27 through the chromodomain of 
its Pc proteins thus silencing gene transcription. 
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Several studies have shown that PcG proteins deregulation contributes to 
tumorigenesis in different tissues (Piunti and Pasini 2011). For example, an 
overexpression of Bmi1 and EZH2 was found overexpressed in hematological 
diseases (Raaphorst et al. 2000), SUZ12 is up-regulated in colon tumors (Kirmizis 
et al. 2004), while Mel18 has been suggested to act as a tumor-suppressor (Kanno 
et al. 1995). Moreover, genetic ablation of specific PcG genes in mice has 
confirmed their role in embryonic patterning and Hox gene regulation. In fact, Bmi-
1 null mice display hematological and neurological defects, depending on a failure 
in the self-renewal of the relevant stem cells (Lessard and Sauvageau 2003, Park et 
al. 2003).  
Recently, genome-wide chromatin immunoprecipitation (ChIP) analysis have 
identified over 1000 genes that are potential targets of PcG-mediated repression, 
many of which are implicated in the maintenance of pluripotency (Bracken et al. 
2006, Tolhuis et al. 2006). Some evidences are rapidly increasing the idea that PcG 
genes represent a novel class of oncogenes and anti-oncogenes, which, in future 
years, may become central to the development of novel cancer therapies based on 
epigenetic gene silencing (Nakao et al. 2004, Egger et al. 2004). In addition, the 
correlation between PcG expression and biological behavior of clinically defined 
cancer subtypes suggests that these genes may also be used as novel diagnostic 
markers (Raaphorst et al. 2004). 
 
 
 
1.2 Characteristics of the CBX7 protein 
 
   CBX7 gene is located on the chromosome 22q13.1 and encodes a novel Pc protein 
of 28.4 kDa and 251 amino acids that contains a characteristic domain called 
“chromodomain” (chromatin organization modifier domain, CD) at the N-terminal 
between the amino acids 10 and 46. The CD is an highly conserved domain and 
represents a 37 amino acids region of homology shared by Heterochromatin protein 
1 (HP1) and Pc proteins (Paro and Hogness 1991). Phylogenetic and sequence 
analysis of the CD show that CBX7 has a great similarity to other known or 
putative Pc proteins like CBX2 (Pc1), CBX4 (Pc2), CBX6 and CBX8 (Pc3) (Figure 
1.2). This similarity is more pronounced respect to the similarity that CBX7 shares 
with HP1 proteins, such as CBX1 (HP1 ), CBX3 (HP1 ), CBX5 (HP1 ), in fact, 
CBX7 does not contain the “chromo-shadow domain”, a hallmark of HP1 proteins. 
Despite of a high degree of conservation, the CD displays significant differences 
for the binding to the histone H3 modifications. Unlike Drosophila Pc, not all 
mammalian Pc-like CDs bind preferentially to tri-methylated Lys 27 on histone H3 
(H3K27me3). In fact, mouse Cbx2 and Cbx7 bind to K9me3 as well as K27me3, 
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Cbx4 has high affinity for K9me3 and Cbx6 and Cbx8 do not significantly bind to 
either modifications, but their CD may bind to another methylation site not yet 
identified or tested (Bernstein et al. 2006). Therefore, CBX7 is able to associate 
with repressive histone modifications, including dimethylated and trimethylated 
H3K9, as well as trimethylated H3K27 (Bernstein et al. 2006) suggesting that a 
CBX7-containing complex may be able to read histone modifications found in 
promoters of key genes, including those susceptible to cancer-specific DNA 
methylation. 
CBX7 chromodomain contains also specific conserved residues necessary for both 
Pc dimerization and recognition of H3K27me3 (Min et al. 2003). In addition to the 
high homology within the CD, CBX7 displays also homology to Pc proteins in a C-
terminal region (amino acids 231-243) previously defined as Pc box or C-box. Both 
Pc box and CD are necessary for CBX7 function (Jones et al. 2000).  
It has been demonstrated that a fusion protein between CBX7 and the DNA-binding 
domain of Gal4 represses the transcription of a 4xGal4-tk-luc reporter in a dose-
dependent manner, suggesting CBX7 as a transcriptional repressor. Moreover, 
mouse Cbx7 is able to associate with facultative heterochromatin and with the 
inactive X chromosome, indicating the involvement of Cbx7 in the repression of 
gene transcription (Bernstein et al. 2006). It has also been found that the CD of 
CBX7 is able to bind to RNA molecules in vitro and in vivo, and this ability 
elucidates, at least in part, the association of CBX7 and the inactive X chromosome. 
These reports suggest that the capacity of CBX7 to associate with the inactive X 
chromosome and any other region of chromatin depends not only on its CD, but 
also on the combination of histone modifications and RNA molecules present on its 
target sites (Bernstein et al. 2006).  
Similarly to other Pc proteins, CBX7 is able to interact with different Pc group 
members and, in particular, is able to inter-functions with itself and with the ring-
finger protein Ring1, while there is no association with Bmi1, EED or EZH2, 
suggesting that CBX7 is part of different complexes (Gil et al. 2004). In particular, 
CBX7 co-localizes with Ring1 in nuclear distinct foci-like structure (Pc-bodies), as 
demonstrated in several cell lines by immunofluorescence microscopy studies 
(Saurin et al. 1998). 
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Figure 1.2 Phylogenetic analysis of CBX7 and its chromodomain 
(A) Lines grouped by open rectangles represent orthologs of a same CBX7 
protein (name in the right). Full rectangles indicate proteins that cannot be 
considered orthologs of any of the CBX proteins. Pc proteins are shown in blue, 
while HP1 proteins in red. (B) Alignment of the CBX7 chromodomain with that of 
the other known human Polycomb proteins. Similar residues are shown in cyan 
while identical residues are shown in yellow background. (C) Alignment of 
CBX7 Pc box with that of the other known Polycomb proteins. Colors are the 
same reported in (B). 
 
 
 
1.3 Role of CBX7 protein in cancer 
 
   CBX7 is highly expressed in different normal tissues, including brain, kidney, 
heart and skeletal muscle (Gil et al. 2004), while a decreased expression of CBX7 
 A 
 B 
 C 
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seems to be a general event in human tumors. However, its role in carcinogenesis is 
still not clear. Recent studies have characterized CBX7 as a tumor-suppressor 
protein. In fact, the expression of CBX7 gene is strongly decreased in thyroid 
(Pallante et al., 2008), colon (Pallante et al. 2010), bladder (Hinz et al. 2008), 
pancreatic (Karamitopoulou et al. 2010), breast (Mansueto et al. 2010, Hannafon et 
al. 2011) and lung carcinomas (Forzati et al. 2012). Interestingly, its expression 
progressively decreases with the appearance of a highly malignant phenotype. 
However, in several papers CBX7 has been shown to play like an oncogene. In fact, 
CBX7 expression is associated with expansion of cellular lifespan in human 
prostate primary epithelial cells (Bernard et al. 2005) and in mouse fibroblasts 
through the repression of the Ink4a/Arf locus (Gil et al. 2004) while its ablation by 
shRNA treatment is able to inhibit growth of normal cells through induction of the 
Ink4a locus (Gil et al. 2004). Furthermore, CBX7 resulted overexpressed in gastric 
cancer cell lines and gastric tumors where its silencing leads to increased cellular 
senescence, decreased cellular proliferation and migration ability (Zhang et al. 
2010). Finally, CBX7 expression has been reported to be high in human germinal 
center lymphocytes and in human germinal center-derived follicular lymphomas. In 
mouse systems Cbx7 has been shown to enhance T-cell lymphomagenesis and to 
initiate highly aggressive B cell lymphomasin vivo by cooperating with c-Myc 
(Scott et al. 2007). 
 
 
 
1.3.1 CBX7 in thyroid carcinomas 
 
   A decreased expression of CBX7 in relation to differentiation and malignancy 
grade has been observed in human thyroid carcinomas. Thyroid neoplasms 
represent a good model for studying the events involved in epithelial cell multistep 
carcinogenesis. In fact, they include a wide spectrum of lesions with different 
degrees of malignancy. Thyroid tumours can originate from follicular cells or from 
C cells. Follicular cell-derived thyroid neoplasms include benign follicular 
adenomas (FA), which are not invasive and very well differentiated, and 
carcinomas. Thyroid carcinomas are divided into well-differentiated, poorly 
differentiated (PDCT) and undifferentiated anaplastic thyroid carcinomas (ATC). 
Well-differentiated thyroid carcinomas include papillary carcinomas (PTC), that 
represent more than 70% of thyroid tumours, and follicular carcinomas (FTC) that 
represent 10% of thyroid carcinomas. PTC and FTC are not aggressive tumors and 
have a good prognosis (Kondo et al. 2006, Saltman et al. 2006) while PDTC and 
ATC seem to derive from the progression of differentiated carcinomas and display 
a more aggressive behaviour (Van der Laan et al. 1993). Although the ATCs 
represent 2-5% of thyroid malignant tumours, they are one of the most lethal human 
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neoplasms being fast growing, very aggressive and always fatal. CBX7 resulted 
strongly down-regulated in several thyroid carcinoma cell lines with different grade 
of malignancy compared to primary normal thyroid cells. In particular, CBX7 
expression progressively decreased in relation to malignant grade and neoplastic 
stage. Indeed, CBX7 protein levels decreased in an increasing percentage of cases 
going from benign adenomas to papillary, follicular and anaplastic thyroid 
carcinomas (Pallante et al. 2008) (Figure 1.3). The loss of CBX7 expression in 
relation to tumor grade was supported by the analysis of tumors generating in 
transgenic mice expressing several oncogenes under the control of the 
thyroglobulin promoter (Pallante et al. 2008). Moreover, the restoration of CBX7 
expression in thyroid cancer cell lines is able to decrease the formation rate of 
colonies and to reduce cell growth rate with retention of cells in G1 phase. This 
suggesst a critical role of CBX7 in the regulation of transformed thyroid cell 
proliferation (Pallante et al. 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Analysis of CBX7 expression in human thyroid carcinoma samples 
(A) Expression analysis of CBX7 by RT-PCR in thyroid carcinoma cell lines compared to 
the normal human thyroid primary culture cells (NTPC). β-actin was used as control. (B) 
Expression analysis of CBX7 by qRT-PCR in several human papillary (PTC) and anaplastic 
(ATC) thyroid carcinoma samples. Fold Change value represents the CBX7 expression 
levels in samples compared to the mean expression levels of three normal thyroid 
samples. 
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1.3.2 CBX7 in colorectal carcinomas 
 
   The association between the loss of CBX7 expression and an aggressive tumor 
phenotype is an event occurring also in colorectal carcinomas (CRC) (Pallante et al. 
2010). The molecular mechanisms that lead to CRC, both familiar and sporadic, are 
well-known. About the 85% of CRC originate from chromosomal instability 
pathway (CIN), a multistep process leading to a loss of tumor-suppressor genes, 
while the 15% of CRC are characterized by microsatellite instability (MSI), this 
latter caused by deregulation of the DNA damage repair mechanisms (mismatch 
repair, MMR pathway) (Centelles 2012). Recent studies have demonstrated that 
CBX7 expression is reduced or absent in a significant number of CRC samples in 
comparison to the normal colonic mucosa. Interestingly, CBX7 retention is strongly 
associated with the benign phenotype, as observed in colonic adenomas, while its 
loss correlates with tumor grade and with a low survival time of CRC patients 
(Figure 1.4). A significant association has been found between CBX7 expression 
and clinic-pathological parameters in MMR-proficient patients, that do not have 
any alteration of the MMR pathway. In addition, functional studies have shown that 
the restoration of CBX7 expression in CRC cell lines is able to reduce the cellular 
proliferation suggesting an important role in the progression step of colon 
carcinogenesis (Pallante et al. 2010). 
 
 
 
1.3.3 CBX7 in pancreatic carcinomas 
 
   The correlation between the loss of CBX7 expression and the appearance of 
malignant phenotype seem to be a general event in tumorigenesis. This event 
occurs also in pancreatic carcinomas. Pancreatic tumors can originate both from the 
esocrine and the endocrine zone. Benign neoplasms are rare, while malignant 
tumors are very aggressive, invasive and always fatal. Among the latest ones, the 
most frequent carcinoma type is the pancreatic ductal adenocarcinoma that 
originates from a precursor lesions called pancreatic intraepithelial neoplasia 
(PanIN) and becomes an aggressive neoplasm through a multistep progression 
(Karamitopoulou et al. 2010). PanIN are divided in PanIN-1A, -1B, -2, -3 and only 
PanIN-3 neoplasms are associated with the presence of invasive carcinomas in the 
30-50% of cases. By immunohistochemical analysis of a tissue microarray (TMA) 
comprising pancreatic normal samples and in carcinoma samples with different 
grade of malignancy, it has been demonstrated that CBX7 protein expression 
strongly and progressively decreases going from normal pancreatic tissue, to PanIN 
samples to invasive ductal adenocarcinomas (Karamitopoulou et al. 2010). In 
addition, it has been observed that the loss of CBX7 expression is associated with 
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an increasing malignancy grade of pancreatic adenocarcinoma, whereas the 
maintenance of CBX7 expression shows a trend toward a longer survival. In fact, 
patients with carcinomas expressingCBX7 have a longer survival time compared 
with patients having carcinoma not expressing CBX7 (Karamitopoulou et al. 2010) 
(Figure 1.4).  
 
 
 
Figure 1.4 Association between CBX7 expression and survival time of cancer patient 
Kaplan-Meier survival curves showing differences in survival time between patients with 
colon or pancreas tumors positive or negative for CBX7 expression. The expression of the 
CBX7 protein positively correlates with a long survival time. On the contrary, loss of CBX7 
expression is a marker of poor prognosis.  
 
 
 
1.3.4 CBX7 in lung carcinomas 
 
   Lung neoplasms represent one of the principal cause of cancer mortality and its 
incidence is in constant increasing (Christiani 2006, Walker 2008). The World 
Health Organization classification of 2004, actually the standard system used to 
classify lung carcinomas on the basis of their morphological characteristics, 
classifies lung carcinomas in small cell lung cancer (SCLC) and non-small cell 
lung cancer (NSCLC). NSCLC represent the 80% of lung carcinomas and include 
the adenocarcinoma (AD), the squamous cell carcinoma (SCC) and the large cell 
carcinoma (LCC). As thyroid, colon and pancreatic carcinomas, also lung tumors 
are characterized by the loss of CBX7 expression. Immunohistochemical analysis 
have shown that the expression of CBX7 protein is absent in all the AD samples 
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analysed, while its expression is present in the normal tissues. Decreased 
expression is associated with loss of heterozygosity (LOH) at CBX7 locus in the 
50% of carcinoma samples analysed. The role of CBX7 in lung carcinogenesis was 
supported by a lower rate of colonies formation after restoration of CBX7 
expression in lung carcinoma cell lines. The anti-oncogenic role of CBX7 in lung 
carcinogenesis, was also supported by the phenotypical analysis of Cbx7
-/- 
mice. In 
fact, Cbx7
-/-
 mice have an higher incidence to develop lung carcinomas than wild 
type mice, while Cbx7
+/-
 preferentially develop lung adenomas (Forzati et al. 2012). 
This suggests that the loss of CBX7 expression is strongly associated with the 
acquisition of a malignant phenotype and that the maintenance of CBX7 expression 
prevents the malignant transformation of lung tissues. 
 
 
 
1.4 Mechanisms of action of CBX7 protein 
 
   CBX7 is a chromatin protein able to regulate gene transcription by contributing to 
the assembling of macromolecular complexes. Studies performed in our laboratory, 
have characterized different molecular mechanisms by which CBX7 is able to carry 
out its role of transcriptional regulator. In one model CBX7 prevents cancer 
progression through a mechanism involving the interaction with the histone 
deacetylase 2 (HDAC2), a protein that catalyzes the histone deacetylation, thus 
promoting the silencing of gene expression (Marks et al. 2001). In particular, it has 
been shown that CBX7 is able to positively regulate the expression of the CDH1 
gene encoding the E-cadherin, an adhesion protein whose expression decreases 
during the epithelial-mesenchymal transition (EMT), by interacting and inhibiting 
the activity of HDAC2 on the promoter of CDH1 (Federico et al. 2009). 
CBX7 is also involved in the regulation of microRNAs. In fact, we have 
demonstrated that CBX7 protein is able to negatively regulate the expression of 
miR-181b, whose expression is found to be up-regulated in breast carcinomas. 
Moreover, we identified CBX7 as a target of the miR-181b, thus demonstrating that 
the expression of CBX7, in turn, is negatively modulated by the miR-181b, 
suggesting the existence of a loop involved in breast cancer progression (Mansueto 
et al. 2010). 
In addition, a very recent study has demonstrated that CBX7 is able to interact with 
the high mobility group A1 (HMGA1) protein. In particular, we have demonstrated 
that CBX7 protein negatively regulates the expression of the CCNE1 gene, 
encoding the Cyclin-E protein, a key mediator of cell proliferation, through a 
mechanism involving the interaction with HMGA1. In fact, we have found that 
CBX7 is able to interact with and to counteract the activity of HMGA1 on promoter 
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of the CCNE1 gene, thus inhibiting cell proliferation. Moreover, the presence of 
CBX7 on the CCNE1 promoter recruits also the HDAC2 (Forzati et al. 2012). 
It has been demonstrated that CBX7 is directly involved in gene repression and 
promoter DNA hypermethylation of genes that are not expressed in cancer. CBX7, 
in fact, is able to complex with DNA methyltransferase (DNMT) enzymes on the 
promoter of specific genes suggesting a role in the initiation of epigenetic changes 
involving abnormal DNA hypermethylation of genes frequently silenced in adult 
cancer (Mohammed et al. 2009). In cancer, CBX7 has contrasting roles due to the 
cellular context in which it is located and to the different proteins interacting with 
it. In fact, CBX7 silences the expression of the INK4b-ARF-INK4a gene cluster, 
thus promoting cell proliferation and inhibiting cell senescence (Gil et al. 2004). In 
this mechanism is involved the long non-coding RNA (lcnRNA) ANRIL, a mRNA 
transcribed in the antisense orientation of the INK4b-ARF-INK4a gene cluster. In 
particular, the nascent ANRIL lncRNA is transcribed by the RNA Polymerase II at 
the transcription start site (TSS) in the p16
INK4a 
gene and associates with SUZ12 to 
recruit PRC2 complex that initiates H3K27me3. Subsequently, PRC1 is recuited by 
ANRIL through CBX7 chromodomain that binds to H3K27me3 and in turn in the 
maintenance of epigenetic respression of p16
INK4a 
gene expression (Yap et al. 
2010). 
 
 
 
1.5 High Mobility Group A (HMGA) protein family 
 
   In order to understand the role of CBX7 protein in cancer, we searched for its 
partners of interaction involving in the formation of macro-molecular complexes 
that regulate gene transcription. In this context, we identified HMGA1 as an 
important CBX7 interacting protein. The high mobility group A (HMGA) protein 
family is composed of non-histone components of chromatin acting as architectural 
factors able to regulate gene transcription. These proteins are key elements of 
multiprotein complexes comprising transcriptional factors and co-factors that leads 
to the regulation of the expression of several genes.The HMGA proteins share an 
higly conserved structured during evolution. The HMGA proteins comprise 
HMGA1 (isoforms HMGA1a, HMGA1b, HMGA1c) and HMGA2. They are 
characterized by three DNA binding domains containing a specific sequence called 
“AT-hooks”, short basic repeats through which they bind to AT-rich sequences in 
the minor groove of DNA. In addition, they are characterized by an acid C-terminal 
tail that may be involved in protein-protein interaction and in the recruitment of 
specific proteins to the enhanceosome (Reeves et al. 2001).The HMGA proteins are 
encoded by two different genes. The human HMGA1 gene is located on the 
chromosome 6p21 and consists of 8 exons among which only exons from 5 to 8 are 
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transcribed in mRNA: it encodes the HMGA1 protein with a molecular weight of 
19-20 kDa (Friedmann et al. 1993). Exons from 5 to 7 encodes the AT-hook 
domains. The HMGA1 mRNA is subject to alternative splicing process generating 
two HMGA1 isoforms, HMGA1a and HMGA1b. These isoforms differ in their 
sequence for 11 additional amino acids between the first and the second AT-hook 
domains of the HMGA1a protein compared with the sequence of the HMGA1b 
protein (Figure 1.5 A). Both HMGA1a and HMGA1b proteins are the most 
abundant HMGA1 spliced variants in mammalian cells (Friedmann et al. 1993, 
Johnson et al. 1990). Finally, HMGA1c encodes a protein with a molecular weight 
of 26-27 kDa. This isoform is characterized by a 67 nucleotides deletion at RNA 
level in comparison with the other two HMGA1 proteins. This deletion results in a 
frameshift mutation, so the HMGA1 proteins are identical in their first 65 amino 
acids while they differs thereafter (Napgal et al. 1999). The HMGA1c isoform is 
not yet well characterized, but it appears to be the only HMGA1 transcript present 
in normal human and mouse testis (Chieffi et al. 2002) and, it has been shown that 
HMGA1c binds to retinoid acid receptors thus promoting the activation of 
transcription (Napgal et al. 1999).  
The human HMGA2 gene is located on the chromosome 12q13-15 and consists of 5 
transcribed exons. The first three exons encode the AT-hook domains, while the 
fifth exon encodes the C-terminal tail (Hauke et al. 2001, Kurose et al. 2001) 
(Figure 1.5 B).  
Both HMGA1 and HMGA2 genes are widely expressed during embryogenesis while 
their expression is absent or low in adult tissues (Chiappetta et al. 1996). In 
particular, HMGA2 expression is absent both in mouse and human adult tissues, 
while HMGA1 expression is present in low levels in the same tissues (Chiappetta et 
al. 1996, Rogalla et al. 1996). However, the expression of these two genes strongly 
increases in high malignant cells in vitro and in vivo (Giancotti et al. 1989). 
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Figure 1.5 Schematic representation of HMGA proteins.  
(A) HMGA1 gene is located on the chromosome 6 and gives rise to splicing variants that 
differ for 11 amino acids. Each of the protein contains three AT-hooks (green box), that 
bind to DNA, and a C-terminal tail (red box). (B) HMGA2 gene is located on the 
chromosome 12 and gives rise to one single protein. AT-hooks and C-terminal tail colors 
are described in (A).  
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1.6 Mechanisms of action of HMGA proteins 
 
   HMGA proteins do not have transcriptional activity per se, but interact with the 
transcription machinery and alter chromatin structure thus regulating, negatively or 
positively, the expression of several genes. HMGA proteins can interact both with 
DNA and transcriptional factors to generate multi-protein complexes bound to 
DNA. They play roles in assembling and modulating the formation of 
macromolecular complexes involved in different biological processes. HMGA 
proteins directly bind to the DNA and modify its conformation facilitating the 
binding of transcriptional factors (TFs) (Thanos et al. 1992, Thanos et al. 1993) 
(Figure 1.6 A). For example, through this mechanism, HMGA proteins are able to 
regulate the expression of the interferon (IFN)-  gene. In particular, the activation 
of IFN-  gene is due to a multifactor complex assembled on the nucleosome-free 
enhancer region of the gene. This complex includes the NF B factor, the interferon 
regulatory factor, the activating transcriptional factor 2 (ATF2)/JUN and the 
HMGA1a protein (Thanos et al. 1992, Thanos et al. 1993). 
In addition, through the study of the enhancement of transcriptional activity of TF 
serum-response factor mediated by HMGA1a protein, it has been demonstrated that 
HMGA proteins can also influence gene transcription by directly interacting with 
TFs and enhancing their binding affinity to DNA (Chin et al. 1998) (Figure 1.6 B).  
Finally, HMGA proteins are able to  interact with matrix- and scaffold- associated 
regions that are enriched in AT sequences and have high affinity for the nuclear 
matrix. These sequences anchor chromatin to the nuclear scaffold and organize 
topologically independent DNA domains that play functional roles both in DNA 
replication and transcription (Figure 1.6 C). The binding of HMGA proteins to 
these regions leads to activation of gene transcription through the displacement of 
histone H1 by the DNAmolecule (Galande et al. 2002). 
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Figure 1.6 Mechanisms of action of the HMGA proteins. 
HMGA proteins regulate positively or negatively gene expression through several 
mechanisms: (A) they are able to simultaneously interact with DNA and with transcriptional 
factors, thus forming macro-molecular complexes on specific chromatin regions; (B) they 
are able to enhance the affinity of transcriptional factors for the binding to the DNA;(C) they 
are able to alter the chromatin structure, thus promoting or silencing gene expression. 
 
 
 
1.7 Characterization of the HMGA proteins role in cancer 
 
   HMGA proteins were identified for the first time in HeLa S3 cells (Lund et al. 
1983), but the association between their expression and the neoplastic phenotype 
was found by observing changes in nuclear proteins expression following the 
transformation of the rat normal thyroid cell line FRTL5 through the Kirsten 
murine sarcoma virus (KiMSV). In particular, in this system it was observed an 
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increased expression of nuclear proteins showing elevated mobility on gel, that 
were named HMGA (Giancotti et al. 1989). 
During the years, several studies have demonstrated that HMGA1 expression is 
over-expressed in different neoplastic tissues, as pancreas, thyroid, colon, breast, 
lung, ovary, cervix, prostate, head and neck and gastric carcinomas (Fusco and 
Fedele 2007). This finding indicates that HMGA1 might be a candidate biomarker 
for cancer diagnosis and prognosis. In fact, in several papers it has been reported 
that there is a strong correlation between the high expression of HMGA1 gene and 
the malignant tumor phenotype. Moreover, an association was also found between 
the over-expression of HMGA1 and the presence of metastasis and a reduced 
survival. Over-expression of HMGA1 was also observed in several kind of human 
leukaemias (Pierantoni et al. 2003). 
However, in contrast, both heterozygous and homozygous Hmga1-null mice 
develop B-cell lymphomas (Fedele et al. 2006). The contrastating role of HMGA1 
protein in cancer could be explained by the fact the HMGA1 interact with several 
proteins in different cellular environments, therefore, interacting with different 
partners, it is able to regulate gene expression. Recently it has been demonstrated 
that the elevated expression of HMGA1 could be due to a complex cooperation 
between SP1 family members and AP1 factors, induced by the activation of Ras 
signaling: this represents one of the mechanisms leading to over-expression of 
HMGA1 gene in cancer (Cleynen et al. 2007). 
Cytogenetic studies have demonstrated the presence of chromosomal 
rearrangements involving the HMGA 2 locus (12q13-15) in various benign tumors 
of mesenchymal origin, as lipomas, uterine leiomyomas, pulmonary chondroid 
hamartomas, breast fibroadenomas, endometrial polyps, pleomorphic adenomas of 
salivary glands and vulvar aggressive angiomyxoma. Chromosomal rearrangements 
generally involve the third intron of the HMGA2 gene and this leads to a 
deregulation of gene expression, truncation or, more frequently, to a generation of 
fusion genes. These aberrant genes encode chimeric transcripts containing the first 
three exons of HMGA2 and ectopic sequences of other genes. This rearrangement 
generates proteins that still retain the ability to bind to DNA and to interact with 
other proteins, but they lose the 3’ untranslated region (3’UTR) that prevents the 
precise regulation of HMGA2 gene expression. To confirm this hypothesis, recent 
studies have demonstrated that the expression of the HMGA2 gene is regulated by 
microRNAs (miRNAs) that bind to the 3’UTR of the gene thus repressing its 
translation (Lee and Dutta 2007, D’Angelo et al. 2012). Rearrangments and 
overexpression of the HMGA2 gene have also been observed in non-mesenchymal 
human benign tumors, such as pituitary adenomas (Finelli et al. 2002). Mice 
expressing a truncated form of Hmga2 under the regulatory control of the 
cytomegalovirus (CMV) promoter (Battista et al. 1999) or the histocompatibility 
complex class I H – 2Kb promoter (Arlotta et al. 2000) develop lipomas. A similar 
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phenotype was also observed in mice over-expressing wild type HMGA2. In 
addition, these mice develop pituitary adenomas secreting prolactin and growth 
hormone (Fedele et al. 2002). 
 
 
 
1.8 Genes regulated by HMGA proteins in cancer 
 
   Recently, several studies have characterized the transforming ability of HMGA 
proteins. They have demonstrated that HMGA proteins are able to up- or down-
regulate the expression of genes involved in cell proliferation and cancer 
progression through the interaction with several proteins. In fact, it has been shown 
that HMGA2 induces pituitary adenomas in Hmga2 transgenic mice by binding to 
pRB, a key regulator of cell cycle, and enhancing the activity of E2F1. In particular, 
it has been shown that HMGA2 interacts with pRB, complexed with E2F1, and 
displaces HDAC1 from pRB-E2F1 complex. In this way, HMGA2 promotes the 
acetylation of E2F1, thus stabilizing its “free active” form (Fedele et al. 2006). 
Moreover, HMGA2 is able to positively regulate the CCNA2 gene expression, 
encoding the Cyclin A, by associating with the transcriptional repressor E4F1 
(Tessari et al. 2003) and by enhancing the activity of the AP1 complex (Vallone et 
al. 1997). It has been demonstrated that the over-expression of HMGA2 leads to a 
recruitment of FRA1 on the CCNA2 promoter, inducing the expression of JUNB 
that, in turn, binds to Cyclin A promoter (Casalino et al. 2007). 
Another study has demonstrated the role of HMGA1 protein in the control of cell 
proliferation. HMGA1, in fact, prevents cell apoptosis by interacting with p53. 
HMGA1 is able to bind to p53 in vivo and in vitro interfering with p53-mediated 
transcription of Bcl2-associated X protein (Bax) and cyclin-dependent kinase 
inhibitor 1A (p21Waf1/Cip1). As well, HMGA1 cooperates with p53 to activate the 
transcription of the p53 inhibitor MDM2 (Pierantoni et al. 2006).  
HMGA1 interferes with apoptosis by also interacting with the pro-apoptotic 
homeodomain-interacting protein kinase 2 (HIPK2), promoting its delocalization in 
the cytoplasm, thus inhibiting the p53 apoptotic function (Pierantoni et al. 2007). 
The HMGA proteins are also involved in DNA repair systems. In fact, HMGA1 is 
able to compete with p53 and human MutS homologue proteins (MSH2-MSH6) for 
“Holliday junction” binding, preventing the activation of the mismatch repair 
response (Subramanian et al. 2002). Moreover, HMGA1 is able to negatively 
regulate the expression of genes involved in DNA-damage recognition and 
removal, as BRCA1 (Baldassarre et al. 2003).  
Finally, HMGA proteins are involved in the regulation of epithelial-mesenchymal 
transition, as reported in a recent study demonstrating that transforming growth 
factor β (TGFβ) mediates EMT by inducing HMGA2 (Thuault et al. 2006). 
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1.9 Small integrin-binding ligand N-linked glycoproteins (SIBLINGs) family 
 
   The cell progression toward malignancy requires complex interaction with the 
host tissue. To survive in host tissues, tumor cells needs to elude immune 
surveillance and to overcome extracellular matrix barriers. All these events may be 
carried out through a complex interaction between host tissues and secreted 
proteins, as small integrin-binding ligand N-linked glycoproteins (SIBLINGs). 
SIBLING family consists of five glycophosphoproteins named osteopontin (OPN) 
(secreted phosphoprotein 1, SPP1), bone sialoprotein (BSP), dentin matrix protein 1 
(DMP1), dentin sialophosphoprotein (DSPP) and matrix extracellular 
phosphoglycoprotein (MEPE). The genes encoding the SIBLING proteins are five 
identically orientated tandem genes within a 37500 bp region on chromosome 4. 
They encode small soluble and secreted prosphoproteins sharing common 
functional motifs and domains, including an Arg-Gly-Asp (RGD) motif that binds 
to specific receptors (Bellahcene et al. 1997). The SIBLING name originates from 
their common genetic and biochemical characteristics, not from functional activity. 
They act as modulators of cell adhesion by interacting through RGD or non-RGD 
motifs with cell surface receptors with members of the matrix metalloproteinase 
(MMP) family and with the complement factor H (CFH). By interacting with 
several receptors, they can localize either on cell surface, exhibiting autocrine 
activities, either in the extracellular space where they may function as paracrine 
mediators (Bellahcene et al. 2008). 
SIBLINGs were initially described as glycophosphoproteins associated to 
mineralized tissues and involved in hydroxyapatite crystals formation. However, 
recent studies have found a strongly up-regulation of SIBLINGs in ephitelial 
tumors, frequently exhibiting pathological microcalcification and properties to 
metastasize to bone (Bellahcene et al. 1997). In normal tissues, all SIBLINGs 
undergo post-traductional modifications leading to the formation of a mature 
protein involved in several cellular processes. For example, SPP1 is able to promote 
cell adhesion and motility by interacting with a variety of integrins (Christensen et 
al. 2007). Moreover, through the activation of NFκB signaling, SPP1 and BSP 
positively affect the survival of T lymphocytes and bone marrow-derived 
monocytes and macrophages (Valverde et al. 2005). Recent studies have further 
demonstrated that SIBLING proteins are strongly over-expressed in several human 
carcinomas. In fact, increased expression of BSP was detected in breast (Bellahcene 
et al. 1994), prostate (Waltregny et al. 1998), lung (Bellahcene et al. 1997), thyroid 
(Bellahcene et al. 1998) and pancreas (Kayed et al. 2007) carcinomas. Also DSPP 
levels were found increased in human malignancies as prostate (Chaplet et al. 2006) 
and breast (Bucciarelli et al. 2007) cancers. On the other hand, the expression of 
MEPE seems to be more restricted than the other SIBLINGs, since its expressionis 
associated only with tumors resulting in oncogenic hypophosphatemic osteomalacia 
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(Rohde et al. 2007). Although these proteins play a role in carcinogenesis, the 
SIBLING protein mainly involved in the progression of tumors toward malignancy 
is the osteopontin protein.  
 
 
 
1.10 Characteristics of the SPP1 protein 
 
   SPP1 is a 264-301 amino acids protein that is subject to several post-translational 
modifications, like phosphorylation, glycosylation and cleavage that lead to the 
production of a protein with a molecular weight ranging from 25 to 75 kDa (Young 
et al. 1990). This protein contains a hydrophobic sequence like other secreted 
proteins. In addition, it includes a calcium phosphate apatite binding region, a cell 
attachment RGD sequence, a thrombin cleavage site and two glutamines recognized 
by transglutaminase enzymes (Young et al. 1990). The human OPN gene contains 7 
exons and the full length mRNA is named OPN-a. Alternative splicing of the OPN 
mRNA, occurring in a region upstream of the central integrin binding domain and 
the C-terminal CD44 binding domain, leads to the formation of OPN-b and OPN-c, 
that lack the exon 5 and the exon 4, respectively (Mirza et al. 2008). Only the 
isoform OPN-c seems to be expressed in invasive tumors as observed in breast 
carcinoma samples (Mirza et al. 2008). SPP1 protein can exist as an immobilized 
extracellular matrix molecule in mineralized tissues as well as an intracellular 
protein. It also shows a wide distribution in normal tissues, like kidney (Khan et al. 
2002), breast (Rodrigues et al. 2007), placenta (Joyce et al. 2005) and testes 
(Luedtke et al. 2002). It is also expressed by leukocytes (Iwata et al. 2004), smooth 
muscle cells (Iwata et al. 2004) and highly metastatic cancer cells. SPP1 protein is 
able to mediate cell-matrix and cell-cell communication by interacting with specific 
receptors. In fact, the interaction between SPP1 and cell surface integrins leads to 
the activation of regulatory and structural proteins like focal adhesion kinase (FAK) 
proteins, src and other cytoskeletal proteins (Fong et al. 2009). 
 
 
 
1.11 SPP1 is involved in cancer progression and in the formation of tumor 
metastasis 
 
   Tumor progression includes a sequential series of events that confer a survival 
advantage to transformed cells. In this context, an important role is played by SPP1 
protein. SPP1 is able to regulate cell migration by interacting with different 
integrins, including αvβ1,αvβ3,αvβ5, α4β1, α9β1 and α8β1. Among all of them, the 
heterodimer αvβ3 is the most common associated with the malignant properties of 
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SPP1 (Liaw et al. 1995). SPP1 can also interact with the surface proteoglycan 
CD44 and with its variants expressed by cancer cells (CD44v3-v6) in a RGD-
dependent manner through its carboxy-terminal fragment. In fact, the interaction 
between SPP1 and CD44v6 is sufficient to induce a metastatic phenotype in 
pancreatic carcinoma cells (Gunthert et al. 1991) and to trigger an autocrine 
mechanism sustaining proliferation and invasion of transformed rat thyroid cells 
transformed (Castellone et al. 2004). The binding of SPP1 to CD44 induces cell 
migration through the activation of phospatidyl-inositol 3-kinase (PI3K) and Akt 
pathway, while the binding to αvβ3 is associated with the activation of mitogen-
activated protein kinase (MAPK) pathway that promotes cell proliferation. 
Furthermore, SPP1-αvβ3 complex enhances angiogenesis by increasing VEGFs 
expression (Liaw et al. 1995) and prevents apoptosis through the activation of NF-
κB pathway (Khan et al. 2002) (Figure 1.7).  
Recent studies have demonstrated that SPP1 contributes to the invasion of 
extracellular matrix by promoting the production of MMP family proteins (Philip et 
al. 2001). It has been reported that breast cancer cell lines transfected or treated 
with SPP1showed an increased expression and activity of the urokinase-type 
plasminogen activator (uPA) that activates MMP1 and MMP2 which, in turn, digest 
specific extracellular matrix components (ECM), thus promoting cancer invasion 
and the formation of metastasis (Tuck et al. 1999). 
Another important aspect of the SPP1 protein function is its involvment in the 
control of immunity response. Since this protein is produced by activated 
macrophages, leukocytes and activated T-lymphocytes, it promotes inflammation-
induced cancer growth by enhancing neutrophil and macrophage infiltration. 
Moreover, SPP1 might avoid tumor cells-removal by down-regulating macrophage 
nitric oxide synthase expression and by mediating the binding of CFH to the cell 
surface that inhibits the complement and the cell lysis (Fedarko et al. 2000). 
SPP1 was the first SIBLING found to be overexpressed in human carcinomas. The 
importance of this occurence is due not only to the mechanisms regulated by SPP1, 
but also to the correlation of its expression levels with specific stages of clinical 
progression. Recent studies have in fact demonstrated that high levels of SPP1 
represent a poor prognostic marker in colon (Rohde et al. 2007) and renal (Matusan 
et al. 2006) cancer patients. Moreover, increased plasma levels of SPP1 have been 
found in patient with highly aggressive prostate (Ramankulov et al. 2007), lung 
(Chang et al. 2007), gastric (Wu et al. 2007), hepatocellular (Wu et al. 2007) and 
pancreatic carcinomas (Koopmann et al. 2004), suggesting a role of SPP1 as marker 
for cancer progression and underlining its involvement in the formation of tumor 
metastasis. 
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Figure 1.7 Schematic representation of the pathway activated by the osteopontin 
The osteopontin is able to regulate several cellular mechanisms by interacting with different 
cell surface receptors. In fact, the binding to the αvβ1 and αvβ5 promotes cell migration 
through the activation of the Ras pathway, while the interaction with the CD44 positively 
regulates cell proliferation and survival through the Akt and MAPK pathway. Finally, 
through the interaction with the αvβ3 receptor, the osteopontin is able to activate the NF-κB 
pathway, thus promoting cell adhesion and angiogenesis.  
 
 
 
1.12 Mechanisms of regulation of the SPP1 expression 
 
   Generally, increased amount of the SPP1 protein is associated with an intense 
transcription of the SPP1 gene. Several hormones, cytokines and transcriptional 
factors may influence the expression of this gene. SPP1 human promoter shows a 
conserved region containing a conserved (TTTAAA) TATA box (-27 to -19), an 
inverted CCAAT box (-52 to -46), a CC box (-100 to -93) and an E-box binding 
factors region. Furthermore, there is one 1,25-dihydroxyvitamin D3 response 
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elements (VDREs) upstream the promoter region that is bound by the vitamin D3 
receptor (VDR), and a consensus sequence for the AP1. Vitamin D3 is a strong 
stimulator of SPP1 synthesis in bone and epidermal cells and a marked reduction of 
SPP1 mRNA expression is observed in vitamin-D3-deficient rachitic mice (Chen et 
al. 1996). The expression of SPP1 in bone is also increased by retinoic acid (Manji 
et al. 1998), while it is decreased by bisphosphonates (Sodek et al. 1995) and 
calcitonin (Kaji et al. 1994). Expression of SPP1 is also up-regulated by various 
growth and differentiation factors. Epidermal growth factor (EGF), c-Src and 12-0-
tetradecano iphorbol-l 3-acetate (TPA) enhances SPP1 expression through the 
protein kinase C (PKC), which activates the early response genes JUN and FOS, 
that, in turn, increase SPP1 transcription (Denhardt and Guo 1993). AP-2 is also a 
target of PKC-mediated signalingas well as signaling through cAMP-dependent 
protein kinase A (PKA). 
During pre-implantation, the up-regulation of SPP1 expression is also mediated by 
Oct-4 through a PORE element in the first intron of the gene, while SOX2 represses 
its expression by interacting with a region closely located (Botquin et al. 1998). 
Furthermore, Src is able to positively regulate the SPP1 expression through the 
inverted CCAAT box which is bound by nuclear factor NF-Y (Kim and Sodek 
1999). Since v-src is a transforming viral oncogene originally identified in the Rous 
sarcoma virus (RSV), this regulation established a link between neoplastic 
transformation and increased expression of SPP1 gene. 
More recently, RUNX2 and ETS1 were identified as important positive 
transcriptional regulators of Spp1 expression in murine colorectal cancer cell line 
(Wai et al. 2006), while the tumor-suppressors BRCA1 (El-Tanani et al. 2006), 
phosphatase and tensin homologue (PTEN) (Shao et al. 2007) and the metastasis 
suppressor breast cancer metastasis suppressor 1 (BRMS1) have been found to be 
negative regulators of SPP1 expression (Wu et al. 2012). 
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2. AIM OF THE STUDY 
 
 
 
   CBX7 is a chromatin-binding protein whose expression is strongly down-
regulated in thyroid tumors with a progressive reduction in relation to malignant 
grade and neoplastic stage. Recent studies have shown that the correlation between 
the loss of CBX7 and a highly malignant phenotype with a consequent poor 
prognosis is a general event in oncology. In fact, the loss of CBX7 expression has 
been shown to be associated with increasing malignancy grade of several human 
carcinomas whereas the retention of CBX7 expression has been correlated with a 
longer survival of colon and pancreatic cancer patients (Pallante et al. 2010, 
Karamitopoulou et al. 2010). In this context, the aim of this study is to understand 
the reasons that make the loss of CBX7 expression an important event in 
carcinogenesis.  
Thus, it was performed an investigation of genes associated with cancer progression 
whose expression could be regulated by CBX7 protein. To characterize the role 
played by CBX7 in cancer, we considered to analyze the CBX7 interacting proteins 
to define the molecular mechanisms through which CBX7 is able to exert its 
function of gene transcriptional regulator . 
Besides the study concerning the characterization of the CBX7 role in cancer, 
projects developed during my PhD program regarded the objects of the following 
publications: 
 
1. Piscuoglio S, Zlobec I, Pallante P, Sepe R, Esposito F, Zimmermann A, 
Diamantis I, Terracciano L, Fusco A, Karamitopoulou E. HMGA1 and 
HMGA2 protein expression correlates with advanced tumour grade 
and lymph node metastasis in pancreatic adenocarcinoma. 
Histopathology 2012;60(3):397-404. (Attached at the end). 
 
2. Pallante P, Malapelle U, Berlingieri MT, Bellevicine C, Sepe R, Federico 
A, Rocco D, Galgani M, Chiariotti L, Sanchez-Cespedes M, Fusco A, 
Troncone G. UbcH10 overexpression in human lung carcinomas and its 
correlation with EGFR and p53 mutational status. Eur J Cancer 
2013;49(5):1117-26. (Attached at the end). 
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3. MATERIALS AND METHODS 
 
 
 
3.1 Cell culture and transfections 
 
   HEK 293 (human embryonal kidney) cell line, the anaplastic thyroid carcinoma 
cell line FRO and the papillary thyroid carcinoma cell lines TPC-1 and BC-PAP 
were grown in Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies, 
Grand Island, NY) supplemented with 10% fetal bovine serum, 1% L-glutamine 
10mM, 1% penicillin/streptomycin 100µg/ml (Life Technologies). Normal rat 
thyroid cell line PC Cl3 was cultured in modified F12 medium supplemented with 
5% calf serum (Life Techonologies), 1% L-glutamine 10mM, 1% 
penicillin/streptomycin 100µg/ml and six growth factors (thyrotropic hormone, 
hydrocortisone, insulin, transferrin, somatostatin and glycyl-histidyl-lysine) 
(Sigma, St. Louis, MO) (Fusco et al. 1987). Mouse embryonic fibroblasts (MEFs) 
from Cbx7-knockout mice were established as described elsewhere (Forzati et al. 
2012) and grown in DMEM supplemented by 1% L-glutamine 10mM, 1% 
penicillin/streptomycin100µg/ml and 1% gentamicin 10mg/ml (Life 
Technologies). All cell lines were maintained at 37°C under 5% CO2 atmosphere. 
For transfection procedures it was used Lipofectamine reagent (Life Technologies) 
for HEK 293 cells, Fugene HD reagent (Promega, Fitchburg, WI) for BC-PAP 
cells and Neon Electroporation System (Life Techologies) for FRO and TPC-1 
cells, according to manifacturer’s instructions. FRO cell clones were selected 
using geneticin (G418, Life Technologies) antibiotic at a final concentration of 
1200µg/ml. For migration assays, TPC-1 cells were transfected with a short 
interfering RNA (siRNA) specific for the human SPP1 gene (Flexi Tube Gene 
Solution, GS6696, Qiagen, Hilden, Germany) or with a non-specific siRNA 
control (All Stars Negative Control siRNA AF488, 1027292, Qiagen) at a final 
concentration of 100nM.  
For the inhibition of Cbx7 expression in PC Cl3, rat Cbx7 siRNA (SI01495795 and 
SI01495802, Qiagen) and Nonsilencing Control siRNA (1022076, Qiagen) were 
transfected using Oligofectamine (Life Technologies) according to the 
manufacturer’s racommandations. siRNAs were used at a final concentration of 
100 nM. 
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3.2 Plamid and constructs 
 
   The vector encoding the CBX7 protein fused to the epitope of the P and V 
proteins of the paramyxovirus of simian virus 5 (V5) was constructed by cloning 
the human cDNA sequence in a pcDNA3.1/V5-His-TOPO ® (Life Technologies). 
The CBX7 cDNA was obtained by PCR using the following primers: CBX7 
forward 5’-ATGGAGCTGTCAGCCATC-3’ and CBX7 reverse 5’-
GAACTTCCCACTGCGGTC-3’. The same PCR product was also inserted into a 
pCEFL-HA vector using EcoRI and NotI restriction sites, thus generating a 
plasmid encoding the CBX7 protein fused to the hemagglutinin tag (HA).  
The vector encoding the HMGA1b protein fused to the HA tag was obtained by 
cloning the entire sequence of the HMGA1b in the pCEFL-HA vector using the 
restriction sites EcoRI and NotI, as described elsewhere (Pierantoni et al. 2006). 
The expression of CBX7-V5, CBX7-HA and HMGA1-HA were assessed by 
western blot analysis. 
 
 
 
3.3 Human tissue samples 
 
   The human thyroid cancer tissues, adjacent normal tissues or normal 
contralateral lobes, obtained from surgical specimens, were provided by the 
service of Pathological Anatomy of the Centre Hospitalier Lyon Sud, Pierre 
Bénite, France, and were immediately frozen in liquid nitrogen to subsequently 
perform the extraction of RNA. 
“TissueScanTM Real-Time Lung Cancer Disease Panel III” of cDNAs was 
purchased from Origene (Origene Technologies Inc., Rockville, MD). This lung 
cancer cDNA panel (HLRT103) contains 8 normal lung specimens and 40 lung 
cancer specimens of different histotype, whose clinical pathological features are 
freely available at the following address: http://www.origene.com/qPCR/Tissue-
qPCR-Arrays.aspx 
 
 
 
3.4 cDNA microarray analysis 
 
   In this study we used commercially available GeneChip® Human Gene 1.0 ST 
Arrays (Affymetrix, Santa Clara, CA) to identify genes differentially expressed. 
The whole hybridization procedure was performed following the Affymetrix 
instructions. Briefly, the RNA was extracted from FRO-EV-1 and FRO-CBX7-1 
cells and was used to obtained double strand cDNA by using oligo-dT and T7 
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RNA polymerase. Amplification and labeling processes were verified using a 
GeneChip® Eukaryotic Poly-A RNA Control Kit (Affymetrix) with exogenous 
positive controls. 15 µg of each biotinylated cDNA preparation was denaturated 
and hybridizated in a mixture containing biotinylated hybridization controls 
(GeneChip® Expression Hybridization Controls, Affymetrix). Samples were then 
hybridized onto a GeneChip® Human Gene 1.0 ST Array consisting of 12.625 
probe set each representing a transcript at 45°C for 16 hours at constant rotation 
(60 rpm) in a Hybridization Oven (Affymetrix). Every samples was hybridized and 
analyzed on the microarray chip three times. Microarray scanned images were 
obtained with a GeneChip Scanner (Affymetrix) using the default settings. Images 
were analyzed with Affymetrix Gene Expression Analysis Software (Affymetrix).  
The analysis was performed comparing the gene expression profiling of FRO-
CBX7-1 cells to the gene expression profiling of the FRO-EV-1 cells. The fold 
change values obtained by this analysis indicated the relative change in the 
expression levels between FRO-EV-1 and FRO-CBX7-1 and were used to identify 
genes differentially expressed in these two clone cells. 
 
 
 
3.5 RNA extraction and quantitative (q)RT-PCR 
 
   Total RNA was extracted from cell lines and tissues by using the Trizol reagent 
(Life Technologies) according to the manufacturer’s instruction. The integrity of 
the extracted RNA was then assessed by denaturating agarose gel electrophoresis. 
1µg of total RNA of each sample was used to obtained double strand cDNA with 
the QuantiTect Reverse Transcription Kit (Qiagen) using an optimized blend of 
oligo-dT and random primers according to the manufacturer’s instruction. To 
ensure that RNA samples were not contaminated with DNA, negative controls 
were obtained by performing PCR on samples that were not reverse transcribed 
but identically processed. 
The cDNA obtained in these conditions, was used to evaluate the differential gene 
expression levels by PCR. 
Semiquantitative PCR (RT-PCR) was carried out on cDNA using the GeneAmp 
PCR System 9600 (Applied Biosystems, Foster City, CA). After a first denaturing 
step (94°C for 10 minutes), PCR amplification was performed for 25-30 (variable) 
cycles (94°C for 30 seconds, 55-60°C (variable) for 30 seconds, 72°C for 30 
seconds). 
Here are reported the primer sequences used: 
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MOUSE 
Fos: forward 5’-CGCAGAGCATCGGCAGAAGGG-3’, reverse 5’-
GATTCCGGCACTTGGCTGCA-3’; 
Fosb: forward 5’-AGCTCATCACCCTCCGCCGA-3’, reverse 5’-
CGGGCATTTCCCCGAGACCG-3’; 
Egr1: forward 5’-GGGAGCCGAGCGAACAACCC-3’; reverse 5’-
TGATGGGAGGCAACCGAGTCGT-3’; 
Spp1: forward 5’-GTGGCCCATGAGGCTGCAGT-3’; reverse 5’-
GCCAGAATCAGTCACTTTCACCGGG-3’; 
Spink1: forward 5’-TCAGTGCTTTGGCCCTGCTGAGT-3’, reverse 5’-
TTCTGGGACATCCCGCCACTGC-3’; 
Steap1: forward 5’-GCCATCTTGGCTCTCTTGGCTGTG-3’; reverse 5’-
CCAAAGCGTGTACTGTGCCCAGA-3’; 
Cbx7: forward 5’-CTGGGAGCCTATGGAGCA-3’, reverse 5’-
GGCCCATTGGTCAGGTCT-3’; 
G6pd: forward 5’-CAGCGGCAACTAAACTCAGA-3’, revers 5’-
TTCCCTCAGGATCCCACAC-3’; 
 
Quantitative Real-Time PCR (qRT-PCR) was carried out with the CFX96 
thermocycler (Bio-Rad, Hercules, CA) in 96-well plates using a final volume of 20 
µl. For each of the PCR reaction, we used 10 µl of 2X Sybr Green (Applied 
Biosystems, Foster City, CA), 200 nM of each primer, and 20 ng of the cDNA 
previously generated. Here are reported the primer sequences used:  
 
HUMAN 
FOS: forward 5’-CTACCACTCACCCGCAGACT-3’, reverse 5’-
AGGTCCGTGCAGAAGTCCT-3’;  
FOSB: forward 5’-GGCGGAGGGAGCTGACCGAC-3’, reverse 5’-
CGTAGGGGATCTTGCAGCCCG-3’; 
EGR1: forward 5’-AGCCCTACGAGCACCTGAC-3’, reverse 5’-
GGTTTGGCTGGGGTAACTG-3’ 
SPP1; forward 5’-GGCCACATGGCTAAACCCTGACC-3’, reverse 5’-
TGGAGTCCTGGCTGTCCACAT-3’; 
SPINK1: forward 5’-TAAGTGCGGTGCAGTTTTCA-3’, reverse 5’-
TGAGAAGAAAGATGCCTGTTACC-3’ 
STEAP1: forward 5’-TGGCAATACTGGCTCTGTTGGCT-3’, reverse 5’-
GCGTGTATTGTGCCCAGTAGAAGGG-3’; 
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CBX7: forward 5’-CGAGTATCTGGTGAAGTGGAAA-3’, reverse 5’-
GGGGGTCCAAGATGTGCT-3’ 
G6PD: forward 5’-ACAGAGTGAGCCCTTCTTCAA-3’, reverse 5’-
ATAGGAGTTGCGGGCAAAG-3’ 
 
RAT 
Fos: forward 5’-CAGCATGGGCTCCCCTGTCAAC-3’, reverse 5’-
CACTGCAGGTCTGGGCTGGTG-3’; 
Fosb: forward 5’-AACTTTGACACCTCGTCCCGGGGC-3’, reverse 5’-
TCCTCTTCGGGAGACAGCTGCTGG-3’; 
Egr1: forward 5’-CCTCAAGGGGAGCCGAGCGAA-3’, reverse 5’-
GGAGGCAACCGGGTAGTTTGGC-3’; 
Spp1: forward 5’-GCTTTGCAGTCTCCTGCGGCAA-3’, reverse 5’-
AGACAGGAGGCAAGGCCGAAC-3’; 
Steap1: forward 5’-AGCCTAAGGGGAACCTGGAAGATGA-3’, reverse 5’-
TGGACCGTGTGCGGCAAAGG-3’; 
Cbx7: forward 5’-ATCCGGAAGAAGCGCGTGCG-3’, reverse 5’-
GGCCATGACAAGGCGAGGGTC-3’; 
G6pd: forward 5’-GTGGCCATGGAAAAGCCTGCCT-3’, reverse 5’-
TGGGGTTCCCCACATACTGGCC-3’. 
 
After a polymerase enzyme activation step at 95°C for 10 minutes, the cDNAs 
were denaturated at 95°C for 15 seconds and then amplified at 60°C for 30 
minutes. This denaturation/amplification step was repeted for 40 cycles. At the end 
of the reaction, the analysis of the melting curves obtained showed the specificity 
of the cDNA amplified. Every reaction was carried out in duplicate. Fold mRNA 
overexpression was calculated according to the formula 2
-ΔΔCt
 as previously 
described (Livak et al. 2011). 
 
 
 
3.6 Protein extraction and western blot analysis 
 
   Total protein extracts were obtained by lysing cells in RIPA buffer (20 mM Tris-
HCl pH 7.5, 5 mM EDTA, 150 mM NaCl, 1% Nonidet P40, and a mix of protease 
inhibitors) and then centrifugating at 13000 rpm at 4°C for 30 min. The extracted 
proteins were separated by SDS-PAGE and then transferred onto Immobilon-P 
Transfer membranes (Millipore, Billerica, MA). Membranes were blocked with 
5% non-fat milk proteins and incubated with antibodies (Abs) at the appropriate 
diluitions. Anti-V5 (Invitrogen), anti-HA (Roche Applied Science, Mannheim, 
Germany), anti-CBX7 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) are the 
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Abs used in this study. To validate that equal amounts of protein were loaded, the 
filters were incubated with antibodies against the γ-tubulin and α-vinculin protein 
(Santa Cruz Biotechnology, Inc.). Filters were then incubated with horseradish 
peroxidase-conjugated secondary antibody (1:3000) for 60 min at room 
temperature and the signals were detected by western blotting detection system 
(ECL) (Promega).  
 
 
 
3.7 Luciferase transactivation assay 
 
   HEK 293 cells were transiently co-transfected with a vector encoding CBX7-HA 
or HMGA1b-HA protein and a vector encoding the luciferase gene under the 
transcriptional control of the CBX7-regulated genes. A region spanning 1000 bp 
upstream of the tanscriptional start site (TSS) of these genes was amplified by 
PCR using the following primers: 
FOS-1K: forward 5’-ATAACCACACCTCGCACTCC-3’, reverse 5’-
GGCTCAGTCTTGGCTTCTCA-3’; 
FOSB-1K: forward 5’-TGGCAAGTGCCAAATACAAG-3’, reverse 5’-
TGGCCGTAGCTCTGAGTCTT-3’; 
EGR1-1K: forward 5’-GGGACTAGGGAACAGCCTTT-3’, reverse 5’-
TGGGATCTCTCGCGACTC-3’; 
SPP1-1K: forward 5’-TTCCAAAATCGAATCTGTTCC-3’, reverse 5’-
TGCTGCTGCAGACATCCTC-3’; 
SPINK1-1K: forward 5’-TTCCACAGGCCAATTTAAGG-3’, reverse 5’-
CTGGGACTGGAAGGGTCATA-3’; 
STEAP1-1K: forward 5’-GGGAGGGACGGAGTAAACAT-3’, reverse 5’-
TTCAAGGGACTCACCCACTC-3’. 
 
PCR products where inserted in the pGL3 vector (Promega), upstream to the open 
reading frame of the luciferase gene. All the reporter constructs generated were 
checked for mutations by direct sequencing. A vector expressing the Renilla gene 
under the control of the cytomegalovirus (CMV) promoter was used to normalize 
transfection activity. Protein lysates were obtained 48 hours after transfection and 
luciferase activity was measured for each point by using a Lumat LB9507 
luminometer (Berthold Technologies, Bad Wildbad, Germany) and the Dual-
Luciferase Reporter System kit (Promega). All assays were performed in duplicate 
and are the results of the mean of three independent experiments. 
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3.8 Chromatin immunoprecipitation (ChIP) and Re-ChIP assay 
 
   ChIP and Re-ChIP experiments were performed as reported elsewhere (Federico 
et al. 2009). Briefly,48h after transfection 5x10
6
 HEK 293 cells were cross-linked 
using 1% formaldehyde at room temperature for 10 min to fix the DNA-protein 
complexes. The reaction was then terminated by adding glycine at a final 
concentration of 0.125 mol/L. Cells were lysed in 300 µl of buffer containing 
10mM EDTA, 50mM Tris-HCl pH 8.0, 1% SDS and protease inhibitors and then 
sonicated three times for 10 minutes at maximum settings, obtaining fragments 
between 0.3 and 1.0 kb. The samples were cleared by centrifugation at 14000 rpm 
for 15 minutes at 4°C. After centrifugation, 3% of the supernatants amount was 
used for control of the chromatin obtained (input), and the remaining part of the 
samples was diluted 2.5-fold in Ip buffer (100mM NaCl, 2mM EDTA pH 8.0, 
20mM Tris-HCl pH 8.0, 0.5% Triton X-100 and protease inhibitors). After 3h of 
pre-clearing at 4°C with Protein A Sepharose or Protein G Sepharose saturated 
with Salmon Sperm (Millipore), samples were mixed overnight at 4°C with the 
following specific antibodies: anti-HA (Santa Cruz Biotechnology, Inc.), anti-V5 
(Sigma), anti-CBX7 (Santa Cruz Biotechnology, Inc.) and with aspecific IgG 
(Millipore). Subsequently, the DNA-protein-Antibodies complexes were 
immunoprecipitated with the proteins A/G previously used and the 
immunoprecipitated chromatin was released from the beads through 30 minutes 
incubation with 250 µl of 1% SDS, 0.1M NaHCO3 at 37°C and finally with 
200nM NaCl at 65°C overnight. 
For Re-ChIP assays, complexes from the primary ChIP were eluted with 10 
mmol/L of DTT for 30 minutes at 37°C and then diluted in 250 µl of Re-ChIP 
buffer (20mmol/L Tris-HCl pH 8.1, 1% Triton X-100, 2mmol/L EDTA, 
150mmol/L NaCl). The released complexes were re-immunoprecipitated with the 
indicated second antibodies and then subjected again to the ChIP procedure. 
Crosslink was reversed by an overnight incubation at 65°C with 20 µl of 5M NaCl. 
Subsequently,10 µl 0.5mM EDTA, 20 µl 1M Tris-HCl pH 6.5 and 20 µg of 
Proteinase K were added and then the complexes were incubated for 1 h at 45°C. 
The chromatin immunoprecipitated was purified by phenol/chloroform (Life 
Techonologies), precipitated by two volumes of ethanol and 0,1M NaAc and 
finally analyzed by qRT-PCR using the following primers: 
 
HUMAN 
prom_HQ_C_FOS: forward 5’-TTAGGACATCTGCGTCAGCA-3’, reverse 5’-
GCCTTGGCGCGTGTCCTAATC-3’; 
prom_HQ_FOS_B: forward 5’-ATGGCTAATTGCGTCACAGG-3’, reverse 5’-
GCACTGTCCAGCAAGAGGTC-3’; 
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prom_HQ_EGR1: forward 5’-CTTATTTGGGCAGCACCTTATTTGG-3’, 
reverse 5’-GCTTCGGGGAAGCCTAGA-3’; 
prom_HQ_SPP1: forward 5’-AGGCAAGAGTGGTGCAGAT-3’, reverse 5’-
AGCACTTAGGGATCCCATGA-3’; 
prom_HQ_SPINK1: forward 5’-CCACAACCACAGAGGGAGTT-3’, reverse 5’-
CAGGTTCTGGGAATGTCACC-3’; 
prom_HQ_STEAP1: forward 5’-TAATAAGCCCCCGGGTAATC-3’, reverse 5’-
CCCCTCGCCTTTTGTTTAAT-3’; 
prom_HQ_GAPDH: forward 5’-CCCAAAGTCCTCCTGTTTCA-3’, reverse 5’-
GTCTTGAGGCCTGAGCTACG-3’. 
 
MOUSE 
prom_MQ_C_Fos: forward 5’-CTACACGCGGAAGGTCTAGG-3’, reverse 5’-
GCGCTCTGTCGTCAACTCTA-3’; 
prom_MQ_Fosb: forward 5’-GCCGAGCTCCTTATATGGCTA-3’, reverse 5’-
CACCTGCCCATAGTGTGACC-3’; 
prom_MQ_Egr1: forward 5’-CCACTGCTGCTGTTCCAATA-3’; reverse 5’-
AGCCCTCCCATCCAAGAGT-3’; 
prom_MQ_Spp1: forward 5’-TCATCCCCATTGATGTTTTTC-3’, reverse 5’-
TGCATTTAGAATCCCGGAAG-3’; 
prom_MQ_Spink1: forward 5’-CTGCCCATCCATTCAGAACT-3’, reverse 5’-
AGCTGCATTCCTGACATCCT-3’; 
prom_MQ_Steap1: forward 5’-GACGGCGTAATCGCTACAGA-3’, reverse 5’-
CGAAATCTGCAGTTGTGCAT-3’; 
prom_MQ_Gapdh: forward 5’-TGAGTCCTATCCTGGGAACCATCA-3’, 
reverse 5’-TTTGAAATGTGCACGCACCAAGCG-3’. 
 
 
 
3.9 Cell migration assay 
 
   TPC-1 cells were used to carry out the cell migration assays. 24h after 
transfection, cells were counted using the TC10™ Automated Cell Counter (Bio-
Rad). The transwell motility assays were performed using 8 micron pore, 6.5-mm 
polycarbonate transwell filters (Corning Costar Corp., Cambridge, MA). 
3x10
4
cells suspended in 200 µl serum-free medium were seeded on the upper 
surface of the filters and allowed to migrate toward 300 µl of 10% FBS-containing 
media in the bottom compartment. After 24h, transwell filters were washed three 
times in phosphate buffered saline (PBS) at room temperature and the cells 
migrating to the underside of the filters were fixed and stained with crystal violet 
solution (0,1% crystal violet in 20% of methanol). The cells remaining on the 
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upper surface were removed with a cotton swab. In order to exactly quantify the 
crystal violet staining, samples were de-stained with 1% SDS in 500 µl of PBS. 
The absorbance of the eluates were measured at 540nm in microplate reader (LX 
800, Universal Microplate Reader, BioTek,Winooski, VT, USA). Cell 
proliferation assays were performed using CellTiter96 Aqueous One (Promega) to 
confirm that the effects observed were due to cell migration and not to cell 
proliferation. Extracted RNA and proteins were analyzed to evaluate the 
expression of the transfected vectors.  
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4. RESULTS 
 
 
 
4.1 Generation of stable clones expressing CBX7 
 
   In order to understand the role that the CBX7 protein plays in the process of 
carcinogenesis and cancer progression, we restored the CBX7 expression in a 
human anaplastic thyroid carcinoma cell line (FRO) in which the expression of 
CBX7 is absent. To this aim, we transfected FRO cells with a vector encoding the 
CBX7 protein fused to the HA epitope or with the corresponding backbone vector. 
By this approach, we obtained FRO cell clones stably expressing CBX7-HA (FRO-
CBX7) or carrying the empty vector (FRO-EV). qRT-PCR confirmed the elevated 
expression of CBX7 in the FRO-CBX7 clones compared with the levels observed in 
FRO-EV clones and in FRO wild type (FRO-WT) cells (Figure 4.1 A). Western 
blot analysis confirmed the expression of the CBX7 protein in all the FRO-CBX7 
stable clones generated (Figure 4.1 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Generation of FRO clones stably expressing CBX7 
CBX7 expression analysis. (A) qRT-PCR analysis of CBX7 expression in FRO cells stably 
expressing CBX7-HA (FRO-CBX7) or the backbone vector (FRO-EV). Relative Expression 
value represents the CBX7 expression levels of each sample compared to those observed 
in wild type cells (FRO-WT), assuming that CBX7 expression in WT cells is equal to 1. (B) 
Immunoblot analysis of CBX7-HA protein expressed in FRO-CBX7, FRO-EV and FRO-WT 
cells confirmed the expression of the CBX7 protein in all the FRO-CBX7 clones generated. 
γ-tubulin was used as control of the amount of protein analyzed. 
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4.2 Identification of genes regulated by the CBX7 protein 
 
   To investigate the mechanism by which the loss of CBX7 expression may 
contribute to the acquisition of a malignant phenotype, we analyzed the differential 
gene expression profiling of FRO-CBX7 and FRO-EV clones. RNAs extracted 
from FRO-EV-1 and FRO-CBX7-1 clones were hybridized to an Affymetrix 
oligonucleotide array containing probes corresponding to several thousand human 
transcripts. The expression profiling of the FRO-CBX7-1 cells was then compared 
with the FRO-EV-1 one. By this analysis, we identified several transcripts 
differentially expressed between FRO-CBX7-1 and FRO-EV-1. In particular, we 
found that 53 transcripts (17 up-regulated and 36 down-regulated) had an absolute 
fold change value more than 2.0, while 263 transcripts (103 up-regulated and 160 
down-regulated) showed an absolute fold change value comprised from 1.5 to 2.0 
in FRO-CBX7-1 respect to FRO-EV-1.  
Among the whole set of genes that we found to be regulated by CBX7 in human 
thyroid carcinoma cells, we decided to investigate genes known to play a relevant 
role in the acquisition of a malignant phenotype. For this reason, we focused on 
FBJ murine osteosarcoma viral oncogene homolog (FOS), FBJ murine 
osteosarcoma viral oncogene homolog B (FOSB) and early growth response 1 
(EGR1) genes that were positively regulated, and secreted phosphoprotein (SPP1), 
serine peptidase inhibitor, Kazal type 1 (SPINK1) and six transmembrane epithelial 
antigen of the prostate 1 (STEAP1) genes that, conversely, were negatively 
regulated by CBX7 protein (Table 4.1).  
As a control of microarray analysis, we observed that CBX7 was highly expressed 
in the FRO-CBX7-1 clone used to carry out this experiment (Table 4.1). 
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Table 4.1 Analysis of the cDNA microarray 
 
UP Fold 
Change 
Accession 
Number 
Definition 
    
CBX7 58,01 NM_175709 Chromobox homolog7 
FOS 3,76 NM_005252 v-fos FBJ murine osteosarcoma viral 
oncogene homolog 
LOC93432 2,76 NR_003715 Maltase-glucoamylase-like pseudogene 
FOSB 2,67 NM_006732 FBJ murine osteosarcoma viral oncogene 
homolog B 
C1orf88 2,65 BC101501 Chromosome 1 open reading frame 88 
FLJ25778 2,49 NM_173569 Hypothetical protein FLJ25778 
EGR1 2,45 NM_001964 Early growth response 1 
CHN2 2,44 NM_004067 Chimaerin 2 
LOC200383 2,39 BC015442 Similar to Dynein heavy chain at 16F 
NEK5 2,29 NM_199289 NIMA (never in mitosis gene a)-related 
kinase 5 
    
DOWN Fold 
Change 
Accession 
Number 
Definition 
    
SPINK1 -6,91 NM_003122 Serine peptidase inhibitor, Kazal type 1 
SPP1 -4,64 NM_001040058 Secreted phosphoprotein 1 (osteopontin) 
HLA-DMB -4,6 NM_002118 Major histocompability complex, clas II, 
DM beta 
STEAP1 -3,76 NM_012449 Six transmembrane epithelial antigen of the 
prostate 1 
SEMA3A -3,67 NM_006080 Semaphorin 3° 
KLHL5 -3,26 NM_015990 Kelch-like 5 
SGPP2 -3,22 NM_152386 Sphingosine-1-phosphate phosphatase 2 
REG4 -3,10 NM_032044 Regenerating islet-derived family, member 4 
NMUR2 -2,94 NM_020167 Neuromedin U receptor 2 
FGL1 -2,91 NM_201553 Fibrinogen-like 1 
 
The gene expression profiling of the FRO-CBX7-1 clone was compared to the gene 
expression profiling of the FRO-EV-1 clone. Fold Change value represents gene 
expressions in FRO-CBX7-1 cells compared with those observed in FRO-EV-1 cells. 
Accession number and definition are identicative of the genes identified. Up-regulated 
genes are indicated in green, while the down-regulated genes in red. The observation of 
CBX7 among the up-regulated genes represents a positive control of the experiment. 
 
 
 
Then, by qRT-PCR, we validated the results obtained by the cDNA microarray 
analysis and evaluated the expression of these transcripts in several CBX7-
expressing FRO cell clones. Thus, we confirmed the differential expression of these 
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genes in FRO-CBX7 clones compared to FRO-EV and FRO WT cells (Figure 4.2), 
suggesting a close association between the expression of the CBX7 protein and the 
expression of its regulated genes. 
 
Figure 4.2 Expression analysis of the CBX7-regulated genes 
The expression of the selected genes regulated by CBX7 protein was evaluated by qRT-
PCR. Relative Expression value represents gene expression levels of sample compared to 
those observed in FRO-WT cells, assuming that gene expression in WT cells is equal to 1. 
(A) The expression of the CBX7 up-regulated genes is shown in green. FOS, FOSB and 
EGR1 gene expression increased in FRO-CBX7 clones compared to FRO-EV clones and 
FRO WT cells. (B) The expression of the CBX7 down-regulated genes is shown in orange. 
SPP1, SPINK1 and STEAP1 gene expression decreased in FRO-CBX7 clones compared 
to FRO-EV clones and FRO WT cells.  
 
 
 
4.3 Expression analysis of CBX7-regulated genes in mouse embryonic 
fibroblasts (MEFs) deriving from Cbx7
-/- 
mice 
 
   Subsequently, we verified whether these genes differentially expressed in FRO-
CBX7 cells showed differential expression also in other cell systems, as mouse 
embryonic fibroblasts (MEFs) isolated from Cbx7
-/- 
mice (Forzati et al. 2012). To 
this aim, we analyzed the expression of the genes regulated by CBX7 in Cbx7 
+/-
and Cbx7
-/- 
MEFs. As shown in Figure 4.3, by RT-PCR we found that the 
expression of CBX7 down-regulated genes Spp1, Spink1 and Steap1 increased in 
MEFs heterozygous for Cbx7 and null for Cbx7 gene compared to WT MEFs. On 
the contrary, in accordance with the CBX7-positive regulation of Fos, Fosb and 
Egr1 gene, we found that the expression of these three genes decreased in MEFs 
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from Cbx7
-/- 
 mice while their expression showed intermediate levels in Cbx7
+/- 
MEFs compared to WT MEFs. These data shows that CBX7 protein is able to 
modulate the expression of these genes also in mouse system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Expression analysis of the CBX7-regulated genes in mice embryonic 
fibroblasts (MEFs) system 
Analysis of the expression of CBX7 up-regulated and down-regulated genes in MEFs 
obtained from Cbx7
-/- 
mice by RT-PCR. A decreased expression of Fos, Fosb and Egr1 
gene was observed in MEFs Cbx7
-/- 
compared to MEFs from Cbx7 WT and Cbx7 
+/- 
mice. 
On the contrary, the expression of Spp1, Steap1 and Spink1 was found to be more 
pronunced in MEFs Cbx7
-/- 
than in MEFs from Cbx7 WT and Cbx7
+/- 
mice. Cbx7 expression 
was evaluated to confirm the system used. Gapdh expression was evaluated to normalize 
the amount of RNA used. 
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4.4 Expression analysis of CBX7-regulated genes in rat thyroid system 
 
   To further verify the role of the CBX7 protein in the regulation of these identified 
genes, we evaluated their expression in the normal rat thyroid cell line PC Cl3 in 
which Cbx7 gene is normally expressed. Cbx7 expression was silenced by using 
siRNA approach. After 24h from the siRNA treatment, we confirmed by qRT-PCR 
the silencing of the Cbx7 gene. Then, we observed a reduced expression of the 
CBX7 up-regulated genes Fos, Fosb and Egr1 expression and an increased 
expression of the CBX7 down-regulated genes Spp1 and Steap1, in comparison 
with the expression levels observed in the untreated cells or in those treated with 
the non-silencing control siRNA (scrambled) (Figure 4.4). 
The data obtained from this experiment confirmed that Cbx7 is able to modulate the 
transcription of these genes also in this cellular system. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Gene expression analysis in PC Cl3 cells 
qRT-PCR analysis in PC Cl3 silenced for Cbx7 expression. After 24h from the transfection 
with the siRNA specific for Cbx7, qRT-PCR analysis showed an increased expression of 
Spp1 and Steap1 while a decreased expression of Fos, Fosb and Egr1 was found in 
comparison to the expression levels observed in PC Cl3 cells transfected with the 
scrambled control siRNA (siCTRL). Fold Change value represents the gene expression 
levels of each sample compared to those observed in cells transfected with the control 
siRNA, assuming that expression levels of the control are equal to 1.  
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4.5 CBX7 directly modulates the activity of gene promoters 
 
   Subsequently, in order to understand whether CBX7 was directly involved in the 
differential expression of its regulated genes, we decided to evaluate the direct 
effect of CBX7 on the transcription of these genes. To this aim, we transiently co-
transfected HEK 293 cells with an increasing amount of a vector encoding CBX7-
HA and with a reporter vector carrying the luciferase gene under the control of a 
1000 bp promoter region located upstream of the TSS of each one of the genes 
analyzed. A vector encoding the Renilla gene was used to normalize the luciferase 
signal observed. As shown in Figure 4.5 A, CBX7 enanched the transcriptional 
activity of FOS, FOSB and EGR1 promoters, whereas it repressed the 
transcriptional activity of SPP1, SPINK1 and STEAP1 promoters (Figure 4.5 B). 
Interestingly, the effects of CBX7 on these promoters was dose-dependent, thus 
demonstrating that CBX7 is able to regulate the expression of these genes by 
directly modulating their promoter activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 CBX7 directly modulates the activity of its regulated genes 
HEK 293 cells were transiently co-transfected with increasing amount of a CBX7-
expressing vector and constant amount of a vector encoding the luciferase gene under 
the control of the CBX7-regulated gene promoters. Relative luciferase activity represents 
the luciferase signals obtained in each samples compared to those observed in cells 
transfected with the backbone vector, assuming that the luciferase signals observed in 
backbone-expressing cells are equal to 1. (A) CBX7 was able to positively regulate the 
activity of the FOS, FOSB and EGR1 promoter and (B) to negatively regulate the activity 
of SPP1, STEAP1 and SPINK1 promoter in a dose-dependent manner. 
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4.6 CBX7 protein physically interacts with the promoter region of its regulated 
genes 
 
   CBX7 is a chromatin protein and exerts its functional role by interacting with the 
DNA through its chromodomain (Bernstein et al. 2006). To characterize the 
molecular mechanism by which CBX7 protein acts to regulate genes transcription, 
we decided to evaluate whether CBX7 protein was able to bind to the promoter of 
its regulated genes in vivo. To this aim, we carried out a chromatin 
immunoprecipitation (ChIP) assay in HEK 293 cells transiently transfected with a 
vector encoding the CBX7 protein fused to the V5 tag or with the corresponding 
backbone vector. Cells were cross-linked and chromatin was immunoprecipitated 
with anti-V5 or IgG antibodies. Immunoprecipitated chromatin was subsequently 
analyzed by qRT-PCR using primers spanning the region of these genes promoter. 
We found that anti-V5 antibodies were able to precipitate region from the promoter 
of these genes only in cells transfected with CBX7-V5, demonstrating that CBX7 
directly binds to these promoters in vivo. On the contrary, in cells transfected with 
the empty vector, we did not found any signal of chromatin immunoprecipitated. 
Moreover, no chromatin enrichment was found in samples immunoprecipitated 
with normal rabbit IgG and when primers for the human GAPDH control promoter 
were used (data not shown), indicating that the CBX7 binding is specific for these 
promoters (Figure 4.6).  
To confirm the binding of endogenous CBX7 protein to the promoters of these 
genes, we took also advantage of tissues obtained from Cbx7 knockout mice 
(Forzati et al. 2012). ChIP experiments were performed in kidney and spleen tissues 
obtained from Cbx7
+/+
 and Cbx7
-/-
 mice. Anti-CBX7 antibodies were able to 
recognize endogenous Cbx7 and to precipitate chromatin from Cbx7
+/+
 but not 
from Cbx7
-/-
 tissues,confirming the binding of endogenous Cbx7 to these promoter 
regions (Figure 4.7).  
These ChIP experiments, therefore, indicated that CBX7 physically interacts with 
the promoter regions of these genes in vivo, therefore directly modulating their 
expression. 
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Figure 4.6 CBX7 protein binds to the promoter of its regulated genes 
HEK 293 cells were transiently transfected with a vector encoding the CBX7-V5 protein or 
with the corresponding backbone vector. The chromatin was immunoprecipitated using 
antibodies against the V5 tag. IgG antibodies were used as negative control. The 
chromatin immunoprecipitated was analyzed by qRT-PCR using primers specific for the 
promoter region -300/+40 from the TSS. GAPDH primers were used as control of the 
binding specifity (data not shown). The percentage of IP chromatin represents the amount 
of immunoprecipitated chromatin in each sample compared to the amount of the total 
chromatin extracted and not immunoprecipitated (input). 
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Figure 4.7 Cbx7 binds to the promoter of its regulated genes in mouse tissues 
Chromatin extracted from spleen and kidney of a Cbx7
+/+ 
or Cbx7
-/- 
mice was 
immunoprecipitated using anti-Cbx7 antibodies. IgG antibodies were used as negative 
control. The chromatin immunoprecipitated were analyzed by qRT-PCR using primers 
specific for the promoter region of all the genes analyzed. GAPDH primers were used as 
control of the binding specifity (data not shown). The percentage of IP chromatin 
represents the amount of immunoprecipitated chromatin in each sample compared to the 
amount of the total chromatin extracted and not immunoprecipitated (input). 
 
 
 
4.7 The expression of CBX7-regulated genes is related to CBX7 expression in 
human carcinomas 
 
   Previous studies have shown that CBX7 expression is reduced in thyroid, colon 
and lung carcinomas (Pallante et al. 2008, Pallante et al. 2010, Forzati et al. 2012) 
with protein levels almost completely undetectable in most advanced thyroid 
cancers. For this reason, we hypothesized that the loss of CBX7 gene could be 
involved in advanced stages of thyroid carcinogenesis through the consequent 
modulation of the expression of these identified genes. Therefore, we analyzed 
CBX7 and the selected CBX7-regulated genes expression in a panel of human 
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papillary thyroid carcinomas and in lung carcinomas by qRT-PCR. As shown in 
Figure 4.8 A, the expression of CBX7 is down-regulated in the PTC samples, as we 
expected, as well as the expression of its up-regulated genes FOS, FOSB and 
EGR1, while the expression of SPP1, SPINK1 and STEAP1 genes resulted 
increased. Similarly, in lung carcinoma samples we observed a positive correlation 
between the expression of CBX7 and its up-regulated genes, while an inverse 
correlation was observed between the expression of CBX7 and its down-regulated 
genes (Figure 4.8 B).  
These data, therefore, strongly suggest that the loss of CBX7 gene expression might 
contribute to the appearance of a malignant phenotype by modulating a set of genes 
critical for the progression step of carcinogenesis. 
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Figure 4.8 Analysis of gene expression in human carcinomas 
qRT-PCR analysis. Relative Expression value represents the gene expression levels of 
each sample compared to those observed in the control sample, assuming that the 
expression level observed in the control is equal to 1. Gene expression was analyzed in a 
panel of (A) papillary thyroid and (B) lung carcinoma samples. A positive correlation was 
found between CBX7 and its up-regulated genes (in green) while a negative correlation 
was found between CBX7 and its down-regulated genes (in orange). The expression 
levels were compared to the mean of three normal thyroid gene expression in (A) and to 
the mean of eight normal lung gene expression in (B). 
 
 
 
4.8 HMGA1 protein regulates the expression of the SPP1 gene 
 
   In order to define the role of CBX7 in cancer and to understand why its loss could 
lead to malignancy, we decided to investigate the molecular mechanism by which 
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CBX7 regulates the expression of SPP1, one of its down-regulated gene. We 
focused on this gene because of its importance in cancer progression. Several 
studies, in fact, have shown that the SPP1 gene expression strongly increases in 
different human carcinomas and that, the SPP1 plasma levels are well correlated 
with cancer progression and the formation of tumor metastasis. 
Recently, it has been demonstrated that CBX7 exerts its role of transcriptional 
regulator by interacting with HMGA1 protein. Thus, we decided to evaluate 
whether this mechanism might be involved also in the regulation of the SPP1 gene 
expression. 
First of all, we analyzed the expression of the Spp1 gene in MEFs system null for 
Hmga1, Hmga2 or both genes. By qRT-PCR analysis we observed a decreased 
expression of Spp1 in MEFs in which Hmga proteins were not expressed compared 
with the Spp1 expression levels observed in WT MEFs (Figure 4.9 A). Moreover, 
we found that the reduction of the Spp1 expression was more pronounced in 
Hmga1
-/- 
MEFs than in Hmga2
-/- 
ones, suggesting that the expression of the Spp1 
gene is under the transcriptional control of the Hmga1 protein. Then, to evaluate the 
effect of the HMGA1 protein on the expression of the SPP1 gene, we transiently 
transfected the papillary thyroid carcinoma cell line BC-PAP, that shows low 
expression of the SPP1 gene (Guarino et al. 2005), with increasing amount of a 
vector encoding HMGA1 protein fused to the HA epitope (HMGA1-HA) or with 
the corresponding backbone vector. By qRT-PCR analysis we found that HMGA1 
protein was able to increase the SPP1 gene expression, showing a positive 
transcriptional regulation of the SPP1 gene mediated by the HMGA1 protein 
(Figure 4.9 B). Western blot analysis, performed with an anti-HA antibody, 
confirmed the expression of the HMGA1-HA protein in BC-PAP cells transfected 
(Figure 4.9 C).  
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Figure 4.9 HMGA1 protein regulates the SPP1 expression 
(A) qRT-PCR analysis of Spp1 in mouse embryonic fibroblasts (MEFs) null for Hmga1, 
Hmga2 or both genes showed a reduction of the Spp1 expression levels in Hmga-null 
samples compared with WT cells. Fold Change value represents the Spp1 expression 
levels of each sample compared with those observed in WT MEFs, assuming that the Spp1 
expression observed in WT MEFs is equal to 1. (B) Analysis of the SPP1 gene expression 
by qRT-PCR in BC-PAP cells transfected with increasing amount of a vector encoding the 
HMGA1-HA protein showed an increase of the SPP1 expression. Fold Change value 
represents the SPP1 expression in each sample compared with the levels observed in cells 
transfected with the backbone vector, assuming that the SPP1 expression observed in the 
sample control is equal to 1. (C) Immunoblot analysis was performed to confirm the 
expression of the HMGA1-HA protein. α-vinculin was used as control. 
 
 
 
4.9 HMGA1 enhances the activity of the SPP1 gene promoter 
 
   Subsequently, we evaluated the effect of the HMGA1 protein on the regulation of 
the SPP1 promoter activity. HEK 293 cells were co-transfected with a vector 
encoding the luciferase gene under the control of 1000 bp region upstream the TSS 
of the SPP1 promoter and with increasing amount of a vector encoding HMGA1-
HA protein. A vector encoding the Renilla gene was used to normalize the 
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luciferase signals obtained. As shown in Figure 4.10, HMGA1 was able to enhance 
the transcriptional activity of the SPP1 promoter in a dose-dependent manner, thus 
showing that HMGA1 acts by directly modulating the activity of the SPP1 
promoter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 HMGA1 directly modulates the activity of the SPP1 promoter 
HEK 293 cells were transiently co-transfected with increasing amount of a vector 
encoding the HMGA1-HA protein and with constant amount of a vector encoding the 
luciferase gene under the control of the SPP1 promoter. HMGA1 was able to positively 
regulate the SPP1 promoter activity in a dose-dependent manner. Relative luciferase 
activity represents the luciferase signals obtained in each samples compared with those 
observed in cells transfected with the backbone vector. 
 
 
 
4.10 CBX7 and HMGA1 compete for the binding to the SPP1 promoter 
 
   We have demonstrated that HMGA1 protein is able to transcriptionally regulate 
the SPP1 gene expression by directly modulating the activity of its promoter. Since 
HMGA are chromatin-interacting proteins, we asked whether HMGA1 protein was 
able to physically interact with the promoter region of the SPP1 gene in vivo. To 
this aim we performed a ChIP assay in HEK 293 cell transiently transfected with a 
vector encoding the HMGA1-HA protein or with the corresponding backbone 
vector. The DNA-protein complexes were fixed and then immunoprecipitated with 
antibodies anti-HA epitope. The immunoprecipitated chromatin was finally 
extracted and analyzed by qRT-PCR using primers spanning the promoter region of 
the SPP1 gene. As shown in Figure 4.11 A, we found a chromatin enrichment only 
in cells transfected with the vector encoding the HMGA-HA protein and 
immunoprecipitated with the anti-HA antibodies. No signals was obtained in cells 
transfected with the empty vector or in samples immunoprecipitated with aspecific 
IgG antibodies. Moreover, no DNA amplification was observed using primers 
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specific for the GAPDH promoter, suggesting the specificity of the HMGA1 
binding to the SPP1 promoter. Western blot analysis was carried out to confirm the  
expression of the HMGA1-HA protein transfected (Figure 4.11 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 HMGA1 protein binds to the SPP1 promoter in vivo 
HEK 293 cells were transiently transfected with a vector encoding the HMGA1 protein 
(HMGA1-HA) or with the backbone vector (EV). (A) The chromatin was 
immunoprecipitated using antibodies against the HA tag. IgG antibodies were used as 
negative control. Chromatin samples immunoprecipitated were analyzed by qRT-PCR 
using primers specific for the SPP1 promoter. GAPDH primers were used as control of the 
binding specifity. The percentage of IP chromatin represents the amount of 
immunoprecipitated chromatin in each sample compared with the amount of the total 
chromatin extracted and not immunoprecipitated. (B) Immunoblot analysis confirmed the 
expression of the HMGA1-HA protein. γ-tubulin was used as control to normalize the 
amount of protein used.  
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Since previously we have shown that CBX7 protein interacts with the SPP1 
promoter and since we have recently demonstrated that CBX7 and HMGA1 interact 
each other, we hypothesized that the interaction of these two proteins might take 
place also on the SPP1 promoter. To test this hypothesize, we performed a ChIP 
assay in HEK 293 cells co-transfected with a vector encoding the CBX7-V5 
protein, with a vector encoding the HMGA1-HA protein or with both vectors. The 
DNA-protein complexes were fixed and immunoprecipitated by using antibodies 
against the V5 epitope. The chromatin was then released by the immunocomplexes 
and finally analyzed by qRT-PCR. By this approach, we found that CBX7 was able 
to interact with the SPP1 promoter region, as we expected, but, interestingly, we 
found that in simultaneous presence of CBX7 and HMGA1 proteins the amount of 
chromatin immunoprecipitated was lower than in the presence of only CBX7 
protein, suggesting that CBX7 competes with and counteracts HMGA1 for the 
binding to the SPP1 promoter. No DNA amplification was observed by 
immunoprecipitating chromatin with aspecific rabbit IgG antibodies and by 
performing qRT-PCR with specific primers for the GAPDH promoter, 
demonstrating that the binding is specific for the SPP1 promoter (Figure 4.12 A). 
Furthermore, Re-ChIP assays showed that both CBX7 and HMGA1 protein bind 
together to the SPP1 promoter (data not shown). Western blot analysis was 
performed to confirm the expression of the CBX7-V5 and HMGA1-HA proteins 
(Figure 4.12 B). 
Taken together, these results demonstrate that CBX7 and HMGA1 bind together to 
the human SPP1 promoter in vivo, and, moreover, that the CBX7 protein 
counteracts HMGA1 for the binding to this promoter. 
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Figure 4.12 CBX7 and HMGA1 compete for the binding to the SPP1 promoter 
(A) HEK 293 cells were transfected both with a vector encoding the CBX7-V5 protein and 
the HMGA1-HA protein. The chromatin was immunoprecipitated using antibodies against 
the V5 tag and then analyzed by qRT-PCR using primers spanning the promoter region of 
the SPP1 gene. Primers specific for the GAPDH were used as control for the specifity of 
the binding. The percentage of IP chromatin represents the amount of immunoprecipitated 
chromatin in each sample compared to the amount of the total chromatin extracted and 
not immunoprecipitated. (B) Immunoblot analysis was performed to confirm the 
expression of the CBX7-V5 and HMGA1-HA proteins. ϒ-tubulin was evaluated to 
normalize the amount of protein used. 
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4.11 CBX7 negatively regulates SPP1 expression by counteracting the 
transcriptional activity of HMGA1 
 
   Then, we evaluated the effects of the simultaneous presence of CBX7 and 
HMGA1 proteins on the transcriptional regulation of the SPP1 gene. To this 
aim,we transiently transfected the papillary thyroid carcinoma cell line TPC-1, in 
which the expression levels of SPP1 are elevated, with a vector encoding the 
CBX7-HA protein, the HMGA1-HA protein or both vectors. By qRT-PCR, we 
observed that the SPP1 expression levels decreased in presence of the CBX7 
protein, while it increased when the HMGA1 protein was expressed, as we 
expected. Interestingly, we found that when both proteins are expressed SPP1 
levels are low as well as in the presence of the only CBX7 protein, suggesting that 
the transcriptional activity of CBX7 protein is stronger than the HMGA1 one, and 
that the presence of CBX7 makes HMGA1 protein unable to exert its role of 
positive regulator of the expression of SPP1 (Figure 4.13 A). Western blot analysis 
confirmed the expression of CBX7 and HMGA1 proteins in the samples analyzed 
(Figure 4.13 B). 
 
Figure 4.13 CBX7 and HMGA1 proteins compete for the transcriptional regulation of 
the SPP1 gene 
TPC-1 cells were transfected with a vector encoding the CBX7-HA protein, the HMGA1-HA 
protein or both vector. (A) The SPP1 expression was analyzed by qRT-PCR. Fold Change 
value represents the SPP1 expression levels of each sample compared to the levels 
observed in cells transfected with the backbone vector, assuming that SPP1 expression in 
the control sample is equal to 1. (B) Immunoblot analysis confirmed the expression of the 
CBX7-HA (indicated by the black arrow) and the HMGA1-HA proteins. γ-tubulin was used 
as control.  
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4.12 CBX7 regulates cell migration through the block of HMGA1 and 
suppression of SPP1 expression  
 
   Data obtained so far have shown that CBX7 and HMGA1 proteins are able to 
regulate the SPP1 transcription. In order to evaluate the functional effect due to this 
mechanism, we performed a migration assay in TPC-1 cell line, highly expressing 
SPP1. TPC-1 cells were transfected with a vector encoding CBX7-HA, HMGA1-
HA protein or the corresponding empty vectors. Moreover, at the same time, TPC-1 
cells were transfected with a siRNA directed against the SPP1 mRNA or with a 
scrambled control siRNA. 24h after transfection, cells were seeded in a transwell 
and the migration rate was evaluated after additional 24h. As shown in Figure 4.14 
A, cells transfected with the vector encoding HMGA1-HA protein and the control 
siRNA showed a migration ability comparable to those observed in cells transfected 
with the empty vector or to wild type cells. Moreover, their ability to migrate 
decreased when treated with the siRNA specific for the SPP1 mRNA.  
On the contrary, cells expressing CBX7 protein and treated with the control siRNA 
showed a lower migration rate than wild type cells and those expressing HMGA1-
HA or the empty vector.  
Interestingly, when the expression of SPP1 gene is silenced by the siRNA, cells 
transfected with CBX7-HA showed the same migration rate of CBX7 cells treated 
with the control siRNA, demonstrating that the ability of cells to migrate is due to 
the SPP1 expression regulation mediated by CBX7 and HMGA1 proteins.  
qRT-PCR and western blot analysis showed the differential expression levels of the 
SPP1 gene (Figure 4.14 B and C). Finally, cell proliferation assays were performed 
to confirm that migration results observed were not due to a change of cell 
proliferation rate but they were a specific effect of the cell ability to migrate (data 
not shown). 
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Figure 4.14 CBX7 and HMGA1 proteins modulate cell migration through the 
transcriptional regulation of the SPP1 gene 
Cell migration assay in TPC-1 cells. Cells were co-transfected with a vector encoding the 
CBX7-HA protein or the HMGA1-HA protein or both vectors and with a specific siRNA for 
the SPP1 gene or the control siRNA. (A) After 24h from the transfection, 3x10
4 
cells were 
seeded on the upper surface of the filters and allowed to migrate to the bottom 
compartment. After additional 24h, cells were stained with crystal violet solution. 
Magnification, X40. (B) The SPP1 expression levels were evaluated by qRT-PCR and 
normalized respect to the GAPDH expression levels of each sample. (C) Immunoblot 
analysis was performed to confirm the expression of CBX7-HA (indicated by the black 
arrow) and HMGA1-HA proteins. γ-tubulin was evaluated to normalize the amount of the 
protein used. 
 
 
 
4.13 Analysis of gene expression in human thyroid carcinomas 
 
   In order to understand whether the differential expression of CBX7, HMGA1 and 
SPP1 might play a role in thyroid carcinogenesis, we analyzed by qRT-PCR the 
expression of these three genes in a panel of human thyroid carcinomas of different 
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histotypes. As shown in Figure 4.15, we found a positive correlation between the 
expression of HMGA1 and SPP1, while an inverse correlation was observed 
between these two genes and CBX7. In fact, CBX7 expression levels decreased in 
PTC and follicular-variant papillary thyroid carcinoma (FVPTC) samples and more 
strongly in ATC, while the expression of HMGA1 and SPP1 increased in all 
samples analyzed reaching the highest level in ATC samples. 
These results demonstrated that the expression levels of these three proteins are 
effectively related and tumor progression might be due to the loss of 
CBX7/HMGA1 regulation that, in turn, could lead to the enhancement of the SPP1 
gene expression.  
 
 
Figure 4.15 Expression analysis in human thyroid carcinomas 
qRT-PCR analysis of CBX7, HMGA1 and SPP1 expression in human papillary thyroid 
carcinomas (PTC), follicular variant of papillary carcinomas (FVPTC) and anaplastic 
carcinomas (ATC). A positive correlation was found between SPP1 and HMGA1 gene 
expression (in red and green, respectively), while a negative correlation was found 
between the expression of these two genes and that of CBX7 (in blue). Relative 
Expression value represents gene expression levels of each sample compared to those 
obtained in the mean of three normal thyroid samples, assuming that the gene expression 
of the control is equal to 1. 
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5. DISCUSSION 
 
 
 
   CBX7 is a novel Polycomb protein that regulates gene expression by taking part 
into the formation of macro-molecular complexes thus binding to the chromatin 
structure. The role of CBX7 in carcinogenesis is still not completely defined. 
Recent studies have shown that the expression of CBX7 decreases in thyroid 
carcinomas and that its reduction is more pronounced going from benign adenomas 
to more aggressive carcinomas (Pallante et al. 2008). 
The reduction of CBX7 expression levels seems to be a general feature in human 
carcinogenesis. In fact, it has been observed in several human carcinomas, as colon, 
bladder, breast, pancreatic and lung, and the completely loss of CBX7 expression 
results associated with the most advanced stages and grades of malignancies. 
Indeed, we have found that the loss of CBX7 expression is a marker of poor 
prognosis and shorter survival time of colorectal and pancreatic carcinoma patients 
(Pallante et al. 2010, Karamitopoulou et al. 2010). Therefore, it is reasonable to 
hypothesize that the reduced expression levels of CBX7 might play a key role in the 
process of carcinogenesis and in cancer progression.  
According to this hypothesis, our laboratory has demonstrated that CBX7 is able to 
positively regulate the expression of the E-cadherin gene, a key mediator of the 
EMT (Federico et al. 2009). By this mechanism, CBX7 contributes to prevent the 
acquisition of the malignant features associated with the loss of epithelial 
characteristics and with the acquisition of a mesenchymal phenotype.  
The tumor-suppresor role exerted by CBX7 in cancer is also supported by another 
study regarding the repression of CCNE1 gene, encoding the Cyclin E. By this 
mechanism, CBX7 attenuates the transition from the phase G1 to S of the cell 
cycle, thus negatively regulating cell proliferation (Forzati et al. 2012). 
However, recent studies have demonstrated a correlation between the expression of 
CBX7 and the development of B-cell lymphomas in vivo (Scott et al. 2007) and the 
over-expression of CBX7 was found to be associated with gastric cancer (Zhang at 
al. 2010) and with the expansion of cellular lifespan in human prostate primary 
epithelial cells (Bernard et al. 2005) and in mouse fibroblasts (Gil et al. 2004), thus 
suggesting an oncogenic role of the CBX7 protein. 
In order to better understand the role of the loss of CBX7 gene expression in 
carcinogenesis, we searched for genes whose expression might be regulated by the 
CBX7 protein. To this aim, we restored the CBX7 expression in the thyroid 
carcinoma cell line FRO in which CBX7 is not expressed. Then, we generated FRO 
stably expressing CBX7 (FRO-CBX7) or carrying the corresponding backbone 
vector (FRO-EV), and used the RNA obtained from this cell clones to analyze the 
differential expression profiling through the hybridization of an Affymetrix cDNA 
62 
 
microarray. By this approach, we identified several genes involved in the process of 
carcinogenesis whose expression is regulated by CBX7 protein.  
Among the genes that we found to be up-regulated by CBX7, we concentrated our 
attention on the FOS, FOSB and EGR1 genes. 
FOS and FOSB are transcriptional co-factors that dimerise with the members of the 
JUN family to form the AP-1 complex (Milde-Langosch 2005), an important multi-
protein complex that regulates gene transcription. The role of FOS protein is well 
characterized in different processes, as signal transduction, cell differentiation and 
cell proliferation (Shaulian and Karin 2001). Many studies have described FOS as a 
protein involved in cellular oncogenic transformation, able to modulate the 
expression of several genes important for tumorigenesis, thus causing the down-
regulation of tumor-suppressor genes (Bakin and Curran 1999) and leading to 
invasive growth of cancer cells (Hu et al. 1994). However, recent studies have 
demonstrated that FOS protein has a role in the positive regulation of apoptosis, 
suggesting that this protein may also have tumor-suppressor activities (Mahner et 
al. 2008).  
In addition to FOS, FOSB has been shown to have a role in the progression of 
tumors from different tissues, being down-regulated in poorly differentiated 
mammary carcinomas (Milde-Langosch et al. 2005). Interestingly, the expression 
of the FOS-like antigen 1 (FOSL1) and 2 (FOSL2) genes, that encode other two 
proteins of the FOS family positively involved in tumor cell motility and invasion 
in breast, colorectal and mesothelioma carcinomas (Milde-Langosch et al. 2005), 
were not regulated by CBX7 protein (data not shown). Therefore, the loss of CBX7 
expression may affect the composition of the AP-1 complex, which in turn triggers 
an altered transcription program leading to the appearance of a neoplastic 
phenotype. 
EGR1 is a DNA-binding transcription factor. Several studies have demonstrated 
that the expression of EGR1 is strongly and rapidly induced in response to a wide 
spectrum of stimuli such as serum, growth factors, radiations and stress (Liu et al. 
1998). Moreover, EGR1 exerts its tumor-suppressor role by suppressing growth, 
differentiation and migration of several kind of carcinoma cells (Calogero et al. 
2004, Wu et al. 2001). 
Among all the genes that resulted down-regulated by CBX7 protein, we focused on 
the SPP1, SPINK1 and STEAP1 genes since their elevated expression and 
involvement in human carcinomas.  
SPP1 is a secreted intregrin-binding phosphoprotein involved in the regulation of 
different processes and whose expression has been found strongly over-expressed 
during tumor progression, as observed in colon (Rohde et al. 2007) and renal 
(Matusan et al. 2006) cancer. In particular, elevated plasma levels of the SPP1 
protein are associated with breast advanced tumor stages and poor patient prognosis 
(Tuck et al. 1999). Experimental studies have shown that the SPP1 protein 
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functionally contributed to malignancy, by directly influencing cell and tissue 
properties such as migration and invasion (Tuck et al. 1999), tumor angiogenesis 
(Liaw et al. 1995), and cell survival through the inhibition of apoptosis (Khan et al. 
2002). 
SPINK1 is an enzyme produced by the pancreatic gland and its mainly function is 
to inhibit the effect of the trypsin protein. Recent evidences have shown its role in 
the regulation of cell migration and in tissue repair (Stenman 2002). The over-
expression of SPINK1 is able to promote cell growth in pancreatic cancer by 
stimulating the epidermal growth factor receptor (EGFR) (Ozaki et al. 2009) and 
altered SPINK1 expression has been associated with decreased survival time in 
ovarian and colorectal carcinomas (Paju et al. 2004, Gaber et al. 2009).  
STEAP1 protein is a membrane protein of 339 amino-acids characterized by six 
transmembrane domains. The expression of STEAP1 is low in normal human 
tissues, while it appears to be elevated in all steps of prostate cancer (Hubert et al. 
1999) and in several human cancer cell lines (Alves et al. 2006). However, the role 
of STEAP1 in cancer is not well reported, but it seems that its oncogenic functions 
are due to its role of transporter protein or ion channel in epithelial cells 
(Prevarskaya et al. 2007).  
We first validated the data obtained from the cDNA microarray analysis in all the 
FRO-CBX7 and FRO-EV clones generated and then confirmed the CBX7 
mediated-regulation of all these genes in MEFs system null for the Cbx7 gene. By 
this analysis, we found that the expression of CBX7 up-regulated genes decreased 
more in the Cbx7
-/-
 MEFs (or it is completely silenced, as Egr1) than in Cbx7
+/-
 
MEFs compared to the WT MEFs in which the Cbx7 protein is expressed. In 
contrast, in accordance to the CBX7 gene modulation, we found that the expression 
of Spp1, Spink1 and Steap1 gene increased in Cbx7
-/-
 MEFs in which the Cbx7 
expression is silenced. Furthermore, to enforce the data obtained, we analyzed the 
expression of the CBX7-gene regulated also in the rat normal thyroid cell line PC 
Cl3 in which the Cbx7 expression was silenced. Also in this case, we found a 
positive correlation between the expression of Cbx7 and the expression of its up-
regulated genes, while a negative correlation was found between the expression of 
Cbx7 and the expression of its down-regulated genes, confirming that the 
expression of these genes is regulated by the CBX7 protein. 
Subsequently, we evaluated the effect of the CBX7 protein on the transcriptional 
regulation of these genes and found that CBX7 is able to positively modulate the 
promoter activity of its up-regulated genes and to negatively modulate the promoter 
activity of its down-regulated genes in a dose-dependent manner. Next, ChIP assay 
showed that CBX7 was able to physically bind to the promoter region of its 
regulated genes in vivo. This data was also confirmed by ChIP assay performed in 
tissues obtained from Cbx7
-/- 
and WT mice, showing that only in WT tissues, 
expressing Cbx7, and not in Cbx7
-/- 
ones, we found an enrichment of the 
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immunoprecipitated chromatin, confirming the ability of CBX7 to modulate 
transcription by directly binding to the promoter of its regulated genes. Finally, the 
analysis of CBX7 and the selected CBX7-regulated gene expression in human 
papillary thyroid and lung carcinomas showed a positive or negative correlation 
between CBX7 and the selected CBX7-regulated genes, indicating that the loss of 
CBX7 expression and the consequent de-regulation of several genes is one of the 
processes that finally leads to cancer progression. 
CBX7 is a transcriptional co-factor that exerts its tumor-suppressor activity in 
relation to the interacting proteins localized in the macro-molecular complexes and 
in relation to the tissue compartments in which these different complexes take place 
(Gil and Peters 2006, Whitcomb et al. 2007). To better understand the 
transcriptional regulation exerted by CBX7, we decided to characterize the 
molecular mechanism by which CBX7 is able to regulate the expression of one of 
its down-regulated gene, the SPP1 gene. In particular, we concentrated also on 
proteins that interact with CBX7 leading to the regulation of SPP1. Since we have 
recently demonstrated that CBX7 protein is able to repress the expression of the 
CCNE1 gene by interacting with and counteracting the activity of HMGA1 on the 
CCNE1 promoter (Forzati et al. 2012), we asked whether the same molecular 
mechanism could be involved in the transcriptional regulation of the SPP1 gene.  
HMGA proteins are non-histone chromatin proteins that do not have transcriptional 
activities per se, but they regulate, positively or negatively, gene expression by 
interacting with the DNA structure through their “AT-hooks”, thus modifying the 
conformation of chromatin and promoting the binding of transcriptional factors to 
the DNA (Thanos et al. 1992, Thanos et al. 1993). Indeed, HMGA proteins can also 
influence gene transcription by simultaneously interacting with the DNA and the 
transcriptional factors (Thanos et al. 1992, Thanos et al. 1993) or by enhancing the 
binding affinity of TFs to the chromatin structure (Chin et al. 1998).  
The HMGA expression is high during the development while it appears low or 
absent in adult tissues (Chiappetta et al. 1996, Rogalla et al. 1996). However, the 
expression of HMGA proteins strongly increases in several human and mouse 
carcinomas, suggesting the critical role that these proteins play in human and 
mouse carcinogenesis (Giancotti et al. 1989). Several studies have shown a strong 
association between the over-expression of HMGA proteins and a poorer patient 
prognosis and lower survival time of different carcinomas. The altered HMGA 
expression leads to an anomalous transcriptional regulation of genes involved in the 
control of cell proliferation and migration. In fact, it has been demonstrated that 
HMGA2 protein is able to promote the expression of the CCNA2 gene by 
interacting with E4F1 (Tessari et al. 2003) and by enhancing the AP-1 complex 
activity (Vallone et al. 1997). Moreover, HMGA1 prevents the apoptosis by 
interacting with p53 (Pierantoni et al. 2006) and by re-localizing HIPK2 to the 
cytoplasm, thus inhibiting the apoptosis (Pierantoni et al. 2007). 
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In order to evaluate whether HMGA regulates the expression of the SPP1 gene, by 
qRT-PCR we analyzed the Spp1 expression in MEFs null for Hmga1, Hmga2, or 
both genes. By this analysis, we observed a decreased expression of Spp1 when 
Hmga1, Hmga2 or both proteins were not expressed compared with the Spp1 
expression levels observed in WT MEFs. In particular, we found that the Spp1 
expression reduction was stronger in Hmga1
-/- 
MEFs than in Hmga2
-/- 
ones, 
suggesting that, among the Hmga proteins, Hmga1 had a more effect on the 
regulation of Spp1 transcription. To confirm this data, then we transfected different 
amount of a vector encoding HMGA1-HA protein in the BC-PAP cell line (that 
expresses low levels of the SPP1 protein) and found that SPP1 expression increased 
in relation to the amount of HMGA1 expressed, showing that HMGA1 is able to 
positively regulate the expression of the SPP1 gene. Then, we evaluated the effect 
of the HMGA1 protein on the transcriptional regulation of the SPP1 promoter 
activity and we found that HMGA1 was able to directly increase the transcriptional 
activity of the SPP1 gene in a dose-dependent manner.  
Since HMGA1 is a protein that affects gene expression by interacting with CBX7 
and altering the chromatin structure (Forzati et al. 2012), we asked whether the 
same protein interaction could take place on the SPP1 promoter and whether the 
same transcriptional mechanism could be involved in the regulation of the SPP1 
gene expression. First, ChIP assays showed that HMGA1 physically interacts with 
the promoter region of the SPP1 gene in vivo. Then, interestingly, we found that 
CBX7 and HMGA1 proteins displace each other and compete for the binding to 
this promoter. Moreover, Re-ChIP assays showed that both CBX7 and HMGA1 
protein bind simultaneously the SPP1 promoter (data not shown). Then, to evaluate 
the transcriptional effect of this binding on the SPP1 gene, we analyzed the 
expression of SPP1 in TPC-1 cells expressing CBX7, HMGA1 or both proteins. By 
this analysis, we found that the SPP1 expression decreased in presence of the 
CBX7 protein, whereas it increased after HMGA1 expression. Interestingly, we 
observed that, when both CBX7 and HMGA1 proteins are transfected, the SPP1 
gene expression decreased reaching expression levels comparable to those observed 
when only CBX7 protein was transfected. This result suggests that the CBX7-
HMGA1 complex is involved in modulation of SPP1 expression, and that, in this 
complex, the CBX7 protein had a strong effect on the transcriptional regulation of 
SPP1.  
Furthermore, by functional assays we showed that CBX7 and HMGA1 proteins are 
able to modulate cell migration through the regulation of the SPP1 expression. In 
fact, we found that HMGA1 is able to promote cell migration by enhancing SPP1 
transcription whereas the transfection of CBX7 protein reduces cell motility and the 
SPP1 expression levels. Moreover, when cells expressing the CBX7-HA protein 
were transfected with a siRNA specific for the SPP1 gene, we found a low 
migration rate comparable to that observed in cells CBX7-expressing transfected 
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with the control aspecific siRNA, suggesting that CBX7 negatively regulates SPP1 
gene expression, preventing the cell ability to migrate.  
Finally, expression analysis of the CBX7, HMGA1 and SPP1 gene in a panel of 
thyroid tumors of different histotypes showed a positive correlation between SPP1 
and HMGA1 expression, and a negative correlation between the expression of these 
two genes and the CBX7 gene, suggesting the involvement of the altered expression 
of these genes in the neoplastic transformation of the thyroid gland.  
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6. CONCLUSION 
 
 
 
   Previous studies have demonstrated that CBX7 expression decreases during the 
neoplastic transformation of different human tissues and that its reduction is 
associated to malignant grade and neoplastic stage. The loss of CBX7 expression is 
a marker of poorer prognosis and survival time of cancer patients.  
The purpose of our study was to define the role of CBX7 in cancer and the 
mechanisms by which CBX7 protein is able to exert its function of transcriptional 
regulator. To this aim, we analyzed six genes de-regulated in several human 
carcinomas whose expression is modulated by CBX7 protein. We demonstrated 
that CBX7 is able to regulate the transcriptional activity of these genes by directly 
binding to their promoters. Moreover, by analyzing the expression of CBX7 and its 
up- and down-regulated genes we have found a positive or negative correlation, 
respectively, in a panel of human carcinomas deriving from different tissues. 
Finally, we characterized a molecular mechanism by which CBX7 represses the 
expression of the SPP1 gene, encoding a key mediator of cell migration. We found 
that CBX7 is able to negatively regulate the SPP1 expression by counteracting the 
effect of HMGA1 on the promoter of this gene and counteracting its positive effect 
on the SPP1 gene transcription. 
In conclusion, our data shows the importance of the role played by the CBX7 
protein on the transcriptional regulation of several cancer-related genes, suggesting 
that the loss of CBX7 expression during carcinogenesis may contribute to the 
acquisition of a malignant phenotype. 
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HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph
node metastasis in pancreatic adenocarcinoma
Aims: Pancreatic ductal adenocarcinoma follows a
multistep model of progression through precursor
lesions called pancreatic intraepithelial neoplasia (Pa-
nIN). The high mobility group A1 (HMGA1) and high
mobility group A2 (HMGA2) proteins are architectural
transcription factors that have been implicated in the
pathogenesis and progression of malignant tumours,
including pancreatic cancer. The aim of this study was
to explore the role of HMGA1 and HMGA2 in pancre-
atic carcinogenesis.
Methods and results: HMGA1 and HMGA2 expression
was examined in 210 ductal pancreatic adenocarcino-
mas from resection specimens, combined on a tissue
microarray also including 40 examples of PanIN and
40 normal controls. The results were correlated with
the clinicopathological parameters of the tumours and
the outcome of the patients. The percentage of tumour
cells showing HMGA1 and HMGA2 nuclear immuno-
reactivity correlated positively with increasing malig-
nancy grade and lymph node metastasis. Moreover,
HMGA1 and HMGA2 expression was significantly
higher in invasive carcinomas than in PanINs. No, or
very low, expression was found in normal pancreatic
tissue.
Conclusions: Our results suggest that HMGA1 and
HMGA2 are implicated in pancreatic carcinogenesis
and may play a role in tumour progression towards a
more malignant phenotype.
Keywords: HMGA1, HMGA2, immunoreactivity, pancreatic ductal adenocarcinoma, pancreatic intraepithelial
neoplasia
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Introduction
Pancreatic ductal adenocarcinoma is a common cause
of death from cancer, and has a dismal prognosis with
currently no effective treatment.1 Despite important
advances in our understanding of the molecular
biology of the early stages of neoplastic development,
late molecular events that lead to tumour progression
are largely unknown. Clinicopathological parameters
such as tumour size, lymph node metastases and
evidence of blood vessel or lymphatic invasion have
been proven to be reliable prognostic determinants in
pancreatic cancer.1 The identification of reliable and
reproducible biomarkers would enable better stratifica-
tion of patients, and eventually provide a guide for
individualized therapy. Pancreatic cancer follows a
multistep model of progression through non-invasive
precursor lesions. Pancreatic intraductal lesions have
been classified into four groups of pancreatic intraepi-
thelial neoplasias (PanINs): PanIN-1A, PanIN-1B,
PanIN-2, and PanIN–3.2 PanIN-3 shows severe epi-
thelial dysplasia, and is most likely to progress to
invasive carcinoma.2
The high mobility group A (HMGA) genes encode a
family of non-histone chromatin-binding proteins,
named for their rapid electrophoretic mobility in
polyacrylamide gels.3 HMGA1a and HMGA1b isoforms
result from alternative splicing of HMGA1 mRNA,
whereas HMGA2 is encoded by the related gene
HMGA2.3 HMGA proteins bind the minor groove of
AT-rich DNA sequences. Their DNA-binding domain is
located in the N-terminal region of the protein, and
contains three short basic repeats, the so-called AT-
hooks.4 Once bound to DNA, the HMGA proteins alter
chromatin structure and thereby regulate the tran-
scriptional activity of several genes.5 HMGA proteins
are normally expressed at high levels during embryonic
development, and at very low levels in adult, differen-
tiated tissues.6 HMGA proteins participate, as tran-
scriptional regulators, in many cellular functions,
including regulation of the cell cycle, cell differentia-
tion, senescence, and neoplastic transformation.7 Both
HMGA1 and HMGA2 have been reported to function as
oncogenes and to be overexpressed in almost all
human malignancies so far analysed, including ductal
pancreatic adenocarcinoma.8–20 Moreover, HMGA pro-
tein overexpression has been regarded as a poor
prognostic feature, as it has often been found to
correlate with the presence of metastasis and with
reduced survival.21
The objective of the present study was to investigate
the role of HMGA1 and HMGA2 expression in pancre-
atic carcinogenesis and to evaluate its prognostic
significance. Using immunohistochemistry we analysed
expression in different stages of pancreatic carcinogen-
esis, including invasive adenocarcinomas, PanINs, and
normal pancreatic tissue, in a tissue microarray (TMA)
combining 210 ductal adenocarcinomas of the pan-
creas from resection specimens, 40 cases of PanIN-3,
and 40 normal controls.
Materials and methods
patients and specimens
Formalin-fixed and paraffin-embedded tumours and
control specimens were retrieved from the archives of
the Institute of Pathology, University of Bern. All
tumours and controls were reviewed by an experienced
pathologist (E.K.). Histological subtypes other than
ductal carcinoma were excluded. Tumours were re-
staged according to the American Joint Committee on
Cancer Staging Manual (seventh edition). Representa-
tive tumour areas were selected for the construction of
the TMA. The TMA consisted of 210 surgically-
resected ductal adenocarcinomas of the pancreas, and
included 40 examples of PanIN-3 and 40 normal
controls (normal pancreatic tissue and PanINs were
selected from areas distant from the carcinomas). The
210 patients comprised 110 males and 100 females,
with a mean age of 66.5 years (range: 20–92 years).
The study was approved by the ethics committee of the
University of Bern.
assessment of behaviour
Medical charts were available for 77 of the 210
patients. Of these 77 patients, 60 (78%) died from the
disease, and 7 (9%) were alive with recurrent ⁄ meta-
static disease. The other 10 patients (13%) were alive
without disease. The median follow-up time was
16 months. The clinicopathological features of these
cases with survival information are given in Table 1.
construction of the tma
One core tissue biopsy with a diameter of 0.6 mm was
taken from a representative region of individual paraf-
fin-embedded pancreatic carcinomas (donor blocks),
and placed into a new recipient paraffin block with a
semi-automated tissue-arraying device. The presence of
tumour tissue on the TMA was verified on a haemat-
oxylin and eosin-stained slide. Two to three tissue cores
of each tumour were available for biomarker analysis.
Five-micrometre sections were cut with an adhesive-
coated slide system (Instrumedics, Hackensack, NJ,
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USA) and examined by immunohistochemistry. The
number of samples differed slightly between the indi-
vidual markers, because of variability in the number of
interpretable specimens on TMA sections.
immunohistochemistry
Freshly cut sections of TMA blocks were used for
immunohistochemical staining with anti-HMGA1 and
anti-HMGA2 antibodies. Briefly, punches were de-
waxed and rehydrated in distilled water. Endogenous
peroxidase activity was blocked with 0.5% H2O2. The
sections were incubated with 10% normal goat serum
(Dako Cytomation, Carpinteria, CA, USA) for 20 min,
and then with the primary antibody at room temper-
ature. Optimal staining was achieved after pretreat-
ment in a microwave oven (98C for 30 min, pH 6,
dilution 1:250). Subsequently, sections were incubated
with peroxidase-labelled secondary antibody (Dako
Cytomation) for 30 min at room temperature. 3,3¢-
Diaminobenzidine was used as chromogen. Sections
were then counterstained with Gill’s haematoxylin. As
a positive control, a TMA with various normal tissue
samples was stained in parallel.
The antibodies used for HMGA1 immunostaining
were raised against the synthetic peptide SSSKQQPL-
ASKQ, which is specific for HMGA1. They were affinity
purified against the synthetic peptide.9 For HMGA2
immunohistochemistry, antibodies raised against a
synthetic peptide located in the N-terminal region were
used.22
The specificity of immunolabelling was validated by
the absence of tumour staining when using antibodies
preincubated with the peptide against which the
antibodies were raised (data not shown). Similarly, no
positivity was observed when tumour samples were
incubated with a preimmune serum (data not shown).
immunohistochemical evaluation
Nuclear HMGA1 and HMGA2 staining was scored by
two independent observers (S.P. and L.T.) blinded for
clinical parameters. Slides were screened semiquanti-
tatively for the percentage of positive cells and the
intensity of the signal. At least 100 cells were counted
for each punch. The percentage of positive cells per
number of cells counted was scored in 10 groups from
0 (0–9%) to 9 (91–100%). The intensity of the signal
was graded semiquantitatively into four groups from 0
(no positivity) to 3 (strong positivity). A case was
considered to be positive if belonging at least to group 1
for the percentage (i.e. ‡10%), irrespective of intensity.
In PanINs and normal controls, the epithelial cells of
ductal structures were evaluated.
statistical methods
The selection of clinically important cut-off scores was
based on receiver operating characteristic (ROC) curve
analysis.23,24 At each percentage score, the sensitivity
and specificity for each outcome under study were
plotted, generating an ROC curve. The score having the
closest distance to the point with both maximum
sensitivity and specificity, i.e. point (0.0, 1.0) on the
curve, was selected as the cut-off score leading to the
greatest number of tumours that were correctly clas-
sified as having or not having the outcome. In order to
Table 1. Clinicopathological characteristics of cases with
survival information (N = 77)
Clinicopathological features Frequency, N (%)
Diagnosis
Ductal carcinoma 77 (100.0)
Sex
Female 33 (42.9)
Male 44 (57.1)
Tumour grade
G1 16 (20.8)
G2 42 (54.6)
G3 19 (24.7)
pT stage
pT1 3 (4.1)
pT2 12 (16.2)
pT3 52 (70.3)
pT4 7 (9.5)
pN stage
pN0 27 (38.0)
pN1 44 (62.0)
Metastasis
Absent 72 (93.5)
Present 5 (6.5)
Tumour diameter (mm),
mean ± SD
31.4 ± 14.0
Survival time (months),
median (range)
12.0 (0.5–48.0)
SD, Standard deviation.
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enable the use of ROC curve analysis, the following
clinicopathological features were dichotomized: T stage
(early, T1 + T2; late, T3 + T4), N stage (N0, no lymph
node involvement; N1, any lymph node involvement),
tumour grade (low, G1 + G2; high, G3), and survival
(death from pancreatic carcinoma or alive).
Chi-square tests were used to study the relationship
between HMGA1 and HMGA2 expression and histo-
logical subgroups. Differences in HMGA1 and HMGA2
expression between normal tissue, PanIN and carci-
noma were investigated with the non-parametric
Wilcoxon rank sum test. Univariate survival analysis
was carried out with the Kaplan–Meier log-rank test,
and multivariate analysis with Cox proportional haz-
ards regression. Hazard ratios and 95% confidence
intervals (CIs) were used to determine the effect of each
variable on survival time. In addition, logistic regres-
sion was performed in univariate and multivariate
settings to determine the associations of protein
expression and its independent effect on binary out-
comes. The odds ratios and 95% CIs were evaluated. A
Bonferroni correction for multiple comparisons was
performed. A P-value £0.01 (two-sided) was required
for the association to be statistically significant. All
analyses were carried out with SAS (V9; SAS Institute,
Cary, NC, USA).
Results
analysis of hmga1 and hmga2 express ion by
immunohistochemistry
Table 2 shows the differences in protein expression
between normal pancreas, PanIN, and cancer, and
Table 3 the correlation of HMGA1 and HMGA2
expression with pT stage, pN stage, and tumour grade.
Survival related to protein marker expression is anal-
ysed in Table 4. Some representative images of immu-
nohistochemical staining are illustrated in Figures 1
and 2.
pancreatic carcinomas versus normal
controls
Pancreatic carcinoma cases generally displayed strong
nuclear HMGA1 and HMGA2 immunoreactivity,
whereas absent or very low immunoreactivity was
observed in normal pancreatic tissue. The mean ± stan-
dard deviation (SD) for the percentage of cells showing
HMGA1 and HMGA2 protein expression were found to
be 0 ± 0 and 0.2 ± 0.9, respectively, in normal tissue,
as compared with 26.6 ± 30.5 and 16.3 ± 28.4,
respectively, in carcinomas (P < 0.001; Table 2).
pancreatic carcinoma versus panin
Percentages of cells showing HMGA1 and HMGA2
protein expression were significantly higher in ductal
pancreatic adenocarcinomas (mean ± SD: 26.6 ± 30.5
and 16.3 ± 28.4, respectively) than in PanIN cases
(11.1 ± 15.0 and 2.7 ± 13.5, respectively)
(P < 0.001; Table 2).
pan in versus normal controls
Means for the percentages of cells showing HMGA1
and HMGA2 protein expression were significantly
higher in PanIN cases (11.1 ± 15.0 and 2.7 ± 13.5,
respectively) than in normal tissue (0 ± 0 and
0.2 ± 0.9, respectively) (P < 0.001; Table 2).
Table 2. Differences in marker expression between normal pancreas, pancreatic intraepithelial neoplasia (PanIN) and cancer
Normal PanIN Cancer P-value
HMGA1
n 31 31 183 <0.001
Mean ± SD 0 ± 0 11.1 ± 15.0 26.6 ± 30.5
Median (min)max) 0 (0–0) 5.0 (0–50) 10.0 (0–100)
HMGA2
n 29 37 191 <0.001
Mean ± SD 0.2 ± 0.9 2.7 ± 13.5 16.3 ± 28.4
Median (min)max) 0 (0–5) 0 (0–80) 0 (0–100)
HMGA, High mobility group A; SD, standard deviation.
Expression is given as percentage of immunoreactive cells. Wilcoxon rank sum test.
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Table 3. Protein marker expression related to stage (pT, pN),
and tumour grade
HMGA1 HMGA2
pT stage
pT1–2 25.7 ± 28.7; 15.0 16.0 ± 28.4; 0.0
pT3–4 27.1 ± 31.3; 10.0 16.9 ± 28.9; 0.0
P-value 0.83 0.952
pN stage
pN0 18.3 ± 22.8; 5.0 8.4 ± 19.0; 0.0
pN1 32.7 ± 33.6; 20.0 21.5 ± 32.4; 0.0
P-value 0.012 0.039
Tumour grade
G1–2 22.2 ± 27.3; 10.0 12.0 ± 23.3; 0.0
G3 37.3 ± 35.1; 30.0 26.8 ± 36.0; 5.0
P-value 0.009 0.008
HMGA, High mobility group A.
Expression is given as the percentage of immunoreactive
tumour cells. Mean ± standard deviation; median values.
Wilcoxon rank sum test.
Table 4. Survival analysis related to protein markers using
cut-off scores [median values, namely 10% for HMGA1
(nuclear), and 0% for HMGA2 (nuclear)]*
Total
no. of
patients
No. of
deaths
Median survival
time (months)
(95% CI) P-value
HMGA1
Negative 40 30 14 (10–17) 0.816
Positive 24 20 12.5 (10–22)
HMGA2
Negative 37 27 15 (10–24) 0.196
Positive 26 21 14 (12–18)
CI, Confidence interval; HMGA, high mobility group A.
Log-rank test.
*Similar results were obtained when expression was analysed
as a continuous variable by Cox regression analysis.
A
B
C
Figure 1. Examples of nuclear immunohistochemical detection of
high mobility group A1 (HMGA1). Absent expression in normal
pancreatic tissue (A) and moderate expression in pancreatic intra-
epithelial neoplasia (PanIN) (B), compared with strong, diffuse
expression in pancreatic carcinoma (C).
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protein express ion and tumour grading
Extent of nuclear HMGA1 and HMGA2 expression
showed a positive correlation with higher tumour
grade. Cells within poorly differentiated tumours (grade
3) more frequently expressed HMGA1 and HMGA2
(mean percentage expression ± SD: 37.3 ± 35.1 and
26.8 ± 36.0, respectively) than those in better-differ-
entiated (grade 1 and 2) tumours (22.2 ± 27.3 and
12.0 ± 23.3, respectively) (P = 0.009 and P = 0.008,
respectively; Table 3).
protein express ion and tnm classif ication of
the tumours
HMGA1 and HMGA2 expression showed a significant
association with the pN stage of the tumours.
Mean ± SD percentage expression levels for HMGA1
and HMGA2 were 18.3 ± 22.8 and 8.4 ± 19.0,
respectively, for nodal negative (pN0) carcinomas, as
compared with 32.7 ± 33.6 and 21.5 ± 32.4, respec-
tively, for nodal positive (pN1) carcinomas (P = 0.012
and P = 0.039, respectively; Table 3). No association
was noted between protein expression and pT stage of
the tumours (P = 0.83 and P = 0.952, respectively;
Table 3).
prognostic signif icance
Median survival times were 12.5 and 14 months for
HMGA1-positive and HMGA2-positive tumours,
respectively, as compared with 14 and 15 months for
HMGA1-negative and HMGA2-negative tumours,
respectively. These differences were not statistically
significant (P = 0.816 and P = 0.196, respectively;
Table 4).
Discussion
Although most patients with pancreatic cancer present
with advanced disease, the molecular events involved
in tumour progression, invasion and metastasis are
poorly understood.
In the present study, we investigated the immuno-
histochemical expression of HMGA1 and HMGA2 in
210 cases of ductal adenocarcinoma of the pancreas
combined on a TMA including in addition 40 examples
of PanIN-3 and 40 normal controls.
A major finding was the increasing mean protein
expression of HMGA1 and HMGA2 between normal
pancreatic tissue, PanIN cases, and invasive adenocar-
cinoma (Table 2). Mean HMGA1 and HMGA2 expres-
sion appeared to progressively increase through the
A
B
C
Figure 2. Examples of nuclear immunohistochemical detection of
high mobility group A2 (HMGA2). A, Normal pancreatic tissue
without HMGA2 expression. B, Pancreatic intraepithelial neoplasia
(PanIN) with moderate HMGA2 expression. C, An example of ductal
adenocarcinoma with strong nuclear HMGA2 expression.
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transition from normal tissue to pancreatic cancer.
Moreover, HMGA1 and HMGA2 expression showed a
positive correlation with malignancy grade and neo-
plastic progression, becoming higher with the dediffer-
entiation of the neoplasms and with the presence of
lymph node metastasis. Therefore, our data suggest
that HMGA1 and HMGA2 expression correlates with a
more aggressive phenotype in pancreatic adenocarci-
noma. These findings are in keeping with the recent
studies of Hristov et al.,19,20 who also noted an
association between HMGA1 and HMGA2 expression
and a more malignant phenotype in pancreatic cancer.
HMGA1 was found to correlate with advanced tumour
grade and decreased survival of their patients, whereas
HMGA2 correlated with increasing tumour grade and
lymph node metastasis. However, in our study, both
HMGA1 and HMGA2 showed a positive correlation
with lymph node metastasis. Although we found that
patients with HMGA1 and HMGA2 negative tumours
tended to survive longer, the association with patient
outcome was not statistically significant. This may be
because of the short survival time of most patients with
pancreatic cancer. In addition, Hristov et al.19 reported
that HMGA1 expression correlated with a more
advanced PanIN grade, whereas possible differences
in protein expression between PanIN and adenocarci-
noma were not discussed. In our study, only PanIN-3
lesions were included. Moreover, we demonstrated that
mean protein expression was significantly higher in
pancreatic ductal adenocarcinomas than in PanIN
lesions.
A number of other groups have reported involve-
ment of HMGA genes and proteins in the pathogenesis
of pancreatic cancer. In one study, HMGA1 was found
to be overexpressed in a small number of pancreatic
adenocarcinomas and metastatic lesions, but without
association with tumour grade.25 More recently, Liau
et al.26 reported HMGA1 protein positivity in a high
proportion of ductal pancreatic adenocarcinomas, also
without correlation with tumour differentiation. How-
ever, in this study, in contrast to ours, only staining
intensity was analysed, and the number of carcinomas
was smaller. HMGA1 expression was also found to be
increased in other pancreatic tumours, such as intra-
ductal papillary mucinous neoplasms.26 Studies in
pancreatic ductal adenocarcinoma cell lines have
shown that HMGA1 knockdown decreases cellular
invasion, anchorage-independent cell growth, and
resistance to chemotherapeutic agents.26,27 In addi-
tion, high-level expression of HMGA1 has been
reported in almost all neoplastic tissues, including
colon, breast, lung, ovarian, uterine, prostatic, gastric
and head and neck carcinomas.8–15 HMGA2 has also
been implicated in the development and progression of
human malignancies, including lung adenocarcino-
mas, breast cancer, and squamous cell carcinomas of
the oral cavity.16–18 Additionally, HMGA2 has been
reported to play a role in the epithelial–mesenchymal
transition that takes place during invasion and metas-
tasis.28 A previous study found increased HMGA2
expression by reverse transcription polymerase chain
reaction in ductal pancreatic adenocarcinomas, and
HMGA2 expression by immunohistochemistry.29 How-
ever, associations with grade and outcome were not
included in the analysis, and HMGA2 expression was
also found in pancreatic islet cells and, focally, in non-
neoplastic ductal epithelial cells. In our study, focal
HMGA2 immunoreactivity was also observed in a very
small number of non-malignant ductal epithelial cells.
Regarding the processes underlying the involvement
of HMGA genes in neoplastic transformation, it has
been hypothesized that this probably occurs through
oncofetal transcriptional mechanisms that have not yet
been characterized.21 It has been suggested that the
elevated expression of HMGA1 in tumour cells requires
a complex cooperation between SP1 family members
and AP1 factors, induced by the activation of Ras
GTPase signalling.30 Moreover, the main function of
the HMGA proteins, the regulation of gene transcrip-
tion, is probably based on the ability of HMGA proteins
to down-regulate or up-regulate the expression of
genes that have a crucial role in the control of cell
proliferation and invasion.21 In particular, emerging
evidence suggests that HMGA1 modulates gene expres-
sion, including pathways involved in inflammation,
proliferation, transformation, metastatic progression,
angiogenesis, and DNA repair. Most transcriptional
targets include regulatory elements of nuclear factor-
jB (NF-jB), a mediator of inflammatory pathways,
suggesting that HMGA1 and NF-kB may cooperate to
induce inflammatory signals and drive transforma-
tion.31
One of the advantages of this study is the use of
TMAs, which have provided us with an efficient and
cost-effective way of testing a large number of tumour
specimens. Concerns could be raised about the TMA
technique with regard to the possible limitations in
sampling large, heterogeneous tumours. However,
previous studies have shown comparable results
between whole tissue sections and TMA cores, and
have been able to reproduce numerous clinicopatho-
logical associations previously found with whole tissue
sections.32
In conclusion, we found increasing mean HMGA1
and HMGA2 expression during neoplastic progression
in ductal pancreatic adenocarcinoma, accompanied by
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a positive correlation of protein expression with both
increasing malignancy grade and the presence of
lymph node metastasis. Our results support the idea
that HMGA1 and HMGA2 may play a significant role
in the late stages of pancreatic carcinogenesis and in
the progression towards a more aggressive tumour
phenotype.
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Lung cancer represents the leading cause of cancer
mortality with an increasing incidence worldwide.1,2
The overall 5-year survival rate of the patients aﬀected
by this disease is only 15%.3 Therefore, the high mortal-
ity rate requires the development of a more accurate
early diagnostic tools and new targeted treatments.
Lung cancer is generally divided into two histopa-
thological groups: non-small cell lung cancer (NSCLC)
and small cell lung cancer (SCLC).4 NSCLC, that repre-
sents 80% of lung cancer, is further subdivided into ade-
nocarcinoma (AD), squamous cell carcinoma (SCC) and
large cell carcinoma (LCC). This classiﬁcation is also
based on genetic variations, since NSCLC carries muta-
tions of EGFR (10%), K-ras (20–30%) and p16ink4
(50%), whereas SCLC shows mutations of Rb (90%)
and p14arf (65%).5–7
Therefore, for patients’ treatment it is primarily impor-
tant to distinguish between SCLCand various subtypes of
NSCLC. A small, but not exhaustive, panel of antibodies
including cytokeratin 7, TTF-1 and p63, represent a valid
support for a better deﬁnition of the NSCLC subtypes,8
but the need of highly sensitive and speciﬁc markers to
integrate this small panel is a very important issue.
We retain that one candidate for this role is the
UbcH10 protein, the cancer-related E2 Ubiquitin conju-
gating enzyme,9 an ubiquitin-binding enzyme involved
in the process of ubiquitin-dependent proteolysis of
key regulator molecules of the cell cycle.10–12 Due to
its role played in cell cycle regulation, UbcH10 can be
considered a critical element in cancer progression. In
fact, recent data have shown that the UbcH10 overex-
pression is associated with the late stages of neoplastic
thyroid transformation.13 In human breast carcinomas,
the overexpression of UbcH10 closely correlates with a
more aggressive phenotype.14 Similar ﬁndings have been
reported for ovarian15 and colorectal carcinomas,16
brain cancer17 and various Hodgkin’s (HL) and non-
Hodgkin’s lymphomas (NHL).18 Moreover, it has been
demonstrated that UbcH10 overexpression leads to the
deregulation of cell growth in several carcinoma cell
lines, since the suppression of the UbcH10 synthesis sig-
niﬁcantly reduces cell proliferation.13–15
Therefore, in this study we have analysed UbcH10
expression by reverse transcription polymerase chain reac-
tion (RT-PCR) and immunohistochemistry in a panel of
NSCLC samples. Our results demonstrate that UbcH10nte P. et al., UbcH10 overexpressio
, http://dx.doi.org/10.1016/j.ejca.201was overexpressed inNSCLC compared to normal lung tis-
sue and its overexpression was signiﬁcantly higher in SCC
and LCC than in AD. Moreover, UbcH10 overexpression
was directly correlated with the loss of diﬀerentiation grade
of NSCLC. A direct correlation was found between the
UbcH10 expression levels and the mutational status of
p53, whereas an inverse one was foundwithEGFR. Finally,
we demonstrate that the suppression of UbcH10 expression
byRNAi resulted in a drastic reduction of proliferation and
migration abilities of two lung carcinoma cell lines.
2. Materials and methods
2.1. NSCLC tissue microarray analysis
To evaluate the expression pattern of UbcH10 in lung
cancer, a tissue microarray (TMA), built at the Spanish
National Cancer Research Center (CNIO, Madrid,
Spain) was used. Tissues were provided by the CNIO
Tumour Bank Network (2001–2004), in collaboration
with Spanish Hospitals.19 The study was approved by
the institutional review boards and ethics committees,
and informed consent was obtained from each patient.
Tumourswere reviewed by twopathologists and histolog-
ically classiﬁed according to the 2004 criteria.20 Clinically
relevant data were included (Supplementary Table S1).
p53 and EGFR mutations were detected using PCR and
direct automatic sequencing following standard proto-
cols.19 Formalin-ﬁxed, paraﬃn-embedded tissue blocks
from lung primary tumours were used for TMA construc-
tion, following a previously described protocol.19 Slides
were reviewed by two pathologists, who selected areas
containing tumour cells, avoiding those with necrosis,
inﬂammation and keratinisation. The TMA comprised
fortyAD samples, thirty SCC samples, four LCC samples
and one carcinoid cancer sample, with two cores sampled
for each case.
Ten cases of normal lung tissue were also supplied as
whole sections and included in the staining to assess
UbcH10 expression in non-neoplastic lung.
TMA staining and analysis are reported in detail in
Supplementary Materials and methods.
2.2. Cell cultures and RNA interference
A detailed list of the lung carcinoma cell lines and the
growth conditions are reported in Supplementary Mate-
rials and methods.n in human lung carcinomas and its correlation with EGFR and p53
2.09.033
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oligonucleotides speciﬁc for UbcH10 coding region as
previously reported.13 As negative control, ﬂuorescent
non-silencing controls were used (Catalogue Number
1022563). All siRNA duplexes were purchased from
Qiagen (Qiagen, Valencia, CA) and were transfected
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA)
according to the manufacturer’s recommendations. SiR-
NAs were used at a ﬁnal concentration of 120 nM and
0.5  106 cells were seeded in a 100 mm plate.2.3. Quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
One microgram of total RNA extracted from each
lung carcinoma cell line (Supplementary Materials and
methods) was reverse-transcribed with QuantiTect
Reverse Transcription Kit (Qiagen) according to the
manufacturer’s instructions. Real-Time Quantitative
PCR was carried out with the CFX 96 thermocycler
(Bio-Rad, Hercules, CA) in 96-well plates using a ﬁnal
volume of 20 ll. For PCR we used 10 ll of 2 Sybr
Green (Applied Biosystems, Carlsbad, CA), 200 nM of
each primer and cDNA generated from 20 ng of total
RNA. The conditions used for PCR were 10 min at
95 C and then 45 cycles of 15 s at 95 C and 30 s at
60 C. Each reaction was carried out in triplicate. We
used the 2DDCT method to calculate relative expression
levels. Primers used for qRT-PCR were UbcH10-fw
50-GCCCGTAAAGGAGCTGAG-30, UbcH10-rev 50-
GGGAAGGCAGAAATCCCT-30, G6PD-fw 50-ACA-
GAGTGAGCCCTTCTTCAA-30 and G6PD-rev 50-AT
AGGAGTTGCGGGCAAAG-30. qRT-PCR was also
carried out using “TissueScane Real-Time Lung Cancer
Disease Panel II” of cDNAs purchased from Origene
(Origene Technologies Inc., Rockville, MD). This lung
cancer cDNA panel (Product Code: HLRT102) con-
tained ﬁve normal lung specimens and forty-three lung
cancer specimens of diﬀerent histotypes, whose clinico-
pathological features are freely available on the web
(www.origene.com).2.4. Protein extraction, Western blotting and antibodies
Protein extraction and Western blotting procedures
were carried out as reported elsewhere.21 Brieﬂy, cells
were washed twice in ice-cold PBS, and lysed in JS buﬀer
(50 mM HEPES pH 7.5 containing 150 mM NaCl, 1%
glycerol, 1% Triton X-100, 1.5 mM MgCl2, 5 mM ethyl-
ene glycol tetraacetic acid (EGTA), 1 mM sodium ortho-
vanadate (Na3VO4) and 1 protease inhibitor cocktail).
Protein concentration was determined by the Bradford
assay (Bio-Rad) using bovine serum albumin as stan-
dard, and equal amounts of proteins were analysed by
sodium dodecyl sulphate–polyacrylamide gel electropho-
resis (SDS–PAGE). After blotting, membranes werePlease cite this article in press as: Pallante P. et al., UbcH10 overexpressio
mutational status, Eur J Cancer (2012), http://dx.doi.org/10.1016/j.ejca.201incubated with primary antibodies for UbcH10 (A-650,
Boston Biochem Inc., Cambridge, MA) and b-actin
(Clone AC-15 A5441, Sigma–Aldrich Co., St. Louis,
MO). Membranes were then incubated with the horse-
radish peroxidase-conjugated secondary antibody
(1:3.000) for 60 min (at room temperature) and the reac-
tion was detected with a Western blotting detection sys-
tem (Thermo Scientiﬁc, Rockville, IL).
2.5. Growth curve analysis
To construct the growth curves we used the Cell
Proliferation Kit I (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, MTT) from Roche
(Mannhein, Germany) optimised for spectrophotomet-
ric quantisation of cell proliferation and viability in cell
populations, using the of 96-well plates format. After
siRNA transfection, 5  103 cells were plated in each
well. The absorbance (550–690 nm) was measured by
using a universal Absorbance Microplate Reader
ELx800 (BioTek Instruments Inc., Winooski, VT) at
the following time intervals: 0–24–48–72 h. The data
obtained in this way were normalised with respect to
the control and used to construct growth curves. Dupli-
cates of the same 96-well plates were stained with 0.1%
crystal violet dye for 30 minutes, then, after removing
the solution containing the dye, the colour included into
the cells was eluted with 1% SDS and its concentration
was read in a spectrophotometer (570 nm).21,22 The
measurements were performed according to the time
intervals of 0–24–48–72 h. For growth curve analysis,
three independent experiments were performed and data
were shown as means ± standard deviation (SD).
Fluorescence-activated cell sorting (FACS) analysis of
NSCLC proliferation is fully described in Supplementary
Materials and methods.
2.6. Migration assay
To evaluate the migration rate, we used Transwell cul-
ture chambers (Corning Incorporated, Corning, NY)
adapted to 24-well plates containing special inserts made
of a polycarbonate ﬁlter with 6.5 mm diameter and
8.0 lm pore size. 105 cells were washed three times with
PBS and then resuspended in 1% foetal bovine serum
(FBS) Dulbecco’s modiﬁed Eagle medium (DMEM) cul-
ture medium and seeded in the upper chamber. The
lower chamber was ﬁlled with 600 ll 10% FBS DMEM.
The cells were then incubated at 37 C for 24 h. After
incubation, to block the migration, transwells were
removed from wells and stained with 0.1% crystal violet
in 25% methanol. The cells not migrated were removed
from the top of the transwell with a cotton swab, while
the cells successfully migrated into the lower chamber
remained adherent to the bottom of the membrane.
The percentage of migrated cells was assessed by the
dye elution with 1% SDS and reading absorbance atn in human lung carcinomas and its correlation with EGFR and p53
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Fig. 1. Immunohistochemical detection of the UbcH10 protein in a lung cancer tissue microarray (TMA). The expression pattern of UbcH10 was
analysed to ﬁnd possible association with clinicopathological data of lung carcinoma samples TMA. (A) Left panel. Normal lung tissue shows no
positivity for the UbcH10 expression. The immunostaining pattern shows the progressive increase of UbcH10 expression in representative non-
small cell lung carcinoma (NSCLC) samples of diﬀerent histotypes. It is of note the total absence of UbcH10 staining in the stroma cells. Right
panel. Kruskal–Wallis H test and Mann–Whitney U test were used to correlate UbcH10 expression with NSCLC histotypes. The expression of the
UbcH10 protein (% of stained cells) is higher in the three diﬀerent histological types of NSCLC compared to normal lung parenchyma. While AD
shows a slight increase of UbcH10, a marked overexpression of UbcH10 can be observed in SCC and LCC (p < 0.001). Box and whiskers: Tukey.
NL, normal lung; AD, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma. (B) Left panel. The staining pattern of
representative well and poorly diﬀerentiated lung carcinoma samples shows the absence of UbcH10 expression in the ﬁrst case and, conversely, an
intense UbcH10 staining in the latter case. Right panel. Statistical analyses were conducted to evaluate association between UbcH10 expression and
NSCLC grade: the Spearman’s rho correlation coeﬃcient was calculated (0.390, p = 0.003). The expression of the UbcH10 protein (% of positive
cells) increases with the progressive loss of NSCLC diﬀerentiation degree, going from well- to poorly-diﬀerentiated (p = 0.013). Box and whiskers:
Tukey. WD, well diﬀerentiated; MD: moderately diﬀerentiated; PD: poorly diﬀerentiated.
4 P. Pallante et al. / European Journal of Cancer xxx (2012) xxx–xxx570 nm. Three independent experiments were performed
and data were shown as means ± SD.
2.7. Statistical methods
The statistical analysis on immunohistochemical and
qRT-PCR data was performed employing as appropri-
ate, the Kruskal–Wallis H test, the Mann–Whitney UPlease cite this article in press as: Pallante P. et al., UbcH10 overexpressio
mutational status, Eur J Cancer (2012), http://dx.doi.org/10.1016/j.ejca.201test and the T test. The Spearman’s rho correlation coef-
ﬁcient was calculated where necessary. A p-value < 0.05
was considered statistically signiﬁcant for each analysis.
2.8. Ethics
All the analyses were performed according to the eth-
ical standards of the local ethic committee.n in human lung carcinomas and its correlation with EGFR and p53
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Fig. 2. Association of UbcH10 expression with p53 and EGFR mutations. Mann–Whitney U test analysis was performed to evaluate the
association between UbcH10 expression and p53 and EGFR mutation status. The expression of the UbcH10 protein (% of positive cells) is directly
correlated with p53 mutation status (A) and inversely correlated with mutation status of EGFR (B) in non-small cell lung carcinoma (NSCLC)
samples (p < 0.001 and p = 0.011, respectively). Box and whiskers: Tukey.
P. Pallante et al. / European Journal of Cancer xxx (2012) xxx–xxx 53. Results
3.1. Immunohistochemical analysis of UbcH10 expression
in human NSCLC tissues
We analysed a lung carcinoma TMA comprising sev-
enty-ﬁve cases of diﬀerent histological types (Supple-
mentary Fig. S1) by immunohistochemistry using
antibodies raised against the UbcH10 protein. However,
ﬁve AD samples, six SCC samples, one LCC sample and
one carcinoid sample were excluded from this analysis
because they were not technically suitable. Any normal
lung tissue specimens analysed (n = 10) was negative
for the expression of UbcH10, with only rare single cells
in mitosis showing a weak positive signal for UbcH10
(Fig. 1A). In contrast, a strong UbcH10 expression with
variable degree of intensity was evident in malignant
lesions corresponding to the diﬀerent histological types
of NSCLC (p < 0.001, Kruskal–Wallis H test) (Fig. 1A).
The lung AD samples showed high UbcH10 expres-
sion levels with a median value of 17% (ranging from
3% to 75%) of positive cells (% of positive cells on total
spots per sample, p < 0.001). Overexpression of UbcH10
was even more pronounced in SCC and LCC cases
(p = 0.002, Mann–Whitney U test). In the SCC cases
UbcH10 expression levels had a median value of 27%
(ranging from 8% to 55%, p < 0.001). The same median
value (27%) was also found in the LCC cases, but with a
diﬀerent range of expression (ranging from 25% to 50%,
p < 0.001) (Fig. 1A).
The correlation between UbcH10 expression and
tumour grade was possible in 56 cases, as 19 cases, either
lacked the information on grade or missed the tissue
cores (Supplementary Table S1). As a result of speciﬁc
statistical analysis, we found that the expression of
UbcH10 signiﬁcantly correlated with diﬀerent tumour
grades (p = 0.013, Kruskal–Wallis H test; p = 0.003,
Spearman’s rho-correlation coeﬃcient: 0.390) (Fig. 1B).Please cite this article in press as: Pallante P. et al., UbcH10 overexpressio
mutational status, Eur J Cancer (2012), http://dx.doi.org/10.1016/j.ejca.201Indeed, lower UbcH10 expression levels were found in
the well diﬀerentiated carcinoma samples with a median
value of 22% (ranging from 3% to 42%; p = 0.013)
(Fig. 1B). Conversely, higher levels of UbcH10 expres-
sion were observed in the poorly diﬀerentiated carcino-
mas with a median value of 28% (ranging from 17% to
55%, p = 0.013).
Subsequently, we compared the expression of
UbcH10 with that of Ki-67, a marker of proliferation
commonly used in clinical diagnostics, in order to eval-
uate a possible association of UbcH10 expression with
the carcinoma cell proliferation rate. By using the statis-
tical Spearman’s rho test, we found a signiﬁcant associ-
ation between the expression of the UbcH10 and Ki-67,
since the coeﬃcient of correlation (Spearman’s rho) was
0.414 (p = 0.004) (Supplementary Fig. S2).
3.2. UbcH10 overexpression is directly and inversely
correlated with p53 and EGFR mutational status,
respectively, in NSCLC
Since mutations in the p53 and EGFR genes are a fre-
quent event in lung carcinomas23,24 we analysed the cor-
relation of UbcH10 expression with these mutations. As
shown in Fig. 2A the expression of UbcH10 positively
correlates with the presence of mutations in the p53 gene
(p < 0.001, Mann–Whitney U test). Indeed, the median
value of UbcH10 expression was 16% (ranging from
3% to 55%, p < 0.001) in the carcinoma samples not car-
rying mutations in the p53 gene, whereas it was 30%
(ranging from 8% to 75%, p < 0.001) in the p53-mutated
lung carcinomas. Conversely, the overexpression of
UbcH10 appeared to be inversely correlated with the
presence of mutations in the EGFR gene (p = 0.011,
Mann–Whitney U test) (Fig. 2B). The median value of
UbcH10 expression was 22% (ranging from 3% to
75%, p = 0.011) in the carcinoma samples not carrying
EGFR mutations, while the median value was 9%n in human lung carcinomas and its correlation with EGFR and p53
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Fig. 3. Expression of UbcH10 speciﬁc mRNA in human non-small cell lung carcinoma (NSCLC) specimens. (A) A quantitative reverse
transcription polymerase chain reaction (qRT-PCR) analysis was performed on a cDNA array comprising ﬁve normal lung control tissues and
forty-three NSCLC tissues of diﬀerent histotypes. The Fold Change values indicate the relative change in expression levels between the pool of
normal samples (set equal to 1) and carcinoma samples. The range of variability of UbcH10 expression in normal lung tissues is less than 10%.
UbcH10 is overexpressed in all the carcinomas analysed with a maximum Fold Change of 250. (B) Statistical analyses were conducted to evaluate
the association between UbcH10 and clinicopathological parameters such as histology, stage, grade and sex (Kruskal–Wallis H test and Mann–
Whitney U test). High UbcH10 Fold Change values are signiﬁcantly associated with the progressive loss of cell diﬀerentiation (p = 0.0061). A
particularly signiﬁcant p-value (p = 0.0049) was obtained comparing the G3 versus G1 cases. A general correlation is found with stage and
histotype although the test did not reach the statistical signiﬁcance. No signiﬁcant association was observed when UbcH10 expression was
correlated with the sex of the patients. Box and whiskers: Min to Max.
6 P. Pallante et al. / European Journal of Cancer xxx (2012) xxx–xxx(ranging from 5% to 24%, p = 0.011) in the samples car-
rying EGFR mutations (Fig. 2B).
3.3. qRT-PCR analysis of UbcH10 mRNA expression in
a panel of human lung carcinoma tissues
UbcH10 mRNA expression was evaluated in a panel
of lung carcinoma samples by qRT-PCR analysis. The
UbcH10 overexpression levels showed a Fold ChangePlease cite this article in press as: Pallante P. et al., UbcH10 overexpressio
mutational status, Eur J Cancer (2012), http://dx.doi.org/10.1016/j.ejca.201between 10 and more than 100 in all the samples ana-
lysed. The median value of the UbcH10 Fold Change
was 53.87 (ranging from 1.4 to 250) (Fig. 3A).
Statistical analyses showed that UbcH10mRNAover-
expression was signiﬁcantly correlated with the progres-
sive loss of cellular diﬀerentiation (tumour grade,
p = 0.0061 Kruskal–Wallis H test; G3 versus G1,
p = 0.0049, Mann–Whitney U test). However, no signif-
icant statistical correlation was found between UbcH10n in human lung carcinomas and its correlation with EGFR and p53
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Fig. 4. UbcH10 expression in human lung carcinoma cell lines. (A)
Human lung carcinoma cell lines were analysed for the expression of
UbcH10 by quantitative reverse transcription polymerase chain reac-
tion (qRT-PCR). The expression of b-actin gene was evaluated as a
control to normalise the amount of RNA used. The Fold Change values
indicate the relative change in expression levels between tumour cell
lines and the normal lung tissue sample (LC71 N). (B) Thirty
micrograms of lung carcinoma cell lysates were immunoblotted for
UbcH10 levels. Blot against b-actin was used as protein loading control.
P. Pallante et al. / European Journal of Cancer xxx (2012) xxx–xxx 7expression levels and tumour histotype and stage
(p = 0.0821 and p = 0.0651, respectively,Mann–Whitney
U test) ( Fig. 3B) although a general association was
evident. No correlation was found between UbcH10
expression and the sex and age of the patients (Fig. 3B
and data not shown, respectively).3.4. UbcH10 gene silencing in human lung carcinoma cells
inhibits proliferation and migration
In order to deﬁne the role of UbcH10 overexpression
in lung carcinogenesis, we ﬁrst analysed the expression of
UbcH10 in several lung carcinoma cell lines. As shown in
Fig. 4A, all of them showed UbcH10-speciﬁc mRNA
overexpression with respect to the normal lung tissue
( Fig. 4A). In particular, UbcH10 overexpression was
extremely high (102 Fold Change induction) in the
A459, CALU1, SW1573, H23, H292, H522 and H596
cell lines, while it was less pronounced in A549, H1299
and H460 cell lines (101 Fold Change induction
(Fig. 4A). These data were further conﬁrmed by Western
blot. Indeed, an intense band of 19.6 kDa, correspondingPlease cite this article in press as: Pallante P. et al., UbcH10 overexpressio
mutational status, Eur J Cancer (2012), http://dx.doi.org/10.1016/j.ejca.201to the UbcH10 protein, was present in the A459, A549,
H1299, CALU1 and SW1573 cells (Fig. 4B), whereas this
band was less intense in the H460 cell line (Fig. 4B).
Subsequently, we silenced the expression of UbcH10
protein in A459 and A549 lung carcinoma cell lines.
An eﬃcient reduction of the UbcH10 protein levels
(from 24 to 72 h) was achieved after siRNA transfection
(Fig. 5A). Then, we analysed the growth properties of
the UbcH10-silenced cells. As shown in Fig. 5B, a signif-
icant reduction in cell growth rate was observed in the
A459 and A549 cells transfected with UbcH10 siRNA
in comparison to the non-silencing control transfected
and untransfected cells, as evaluated by MTT assay
(Fig. 5B).
Then, to better characterise the eﬀects of UbcH10 on
cell cycle progression, a ﬂow cytometric analysis was
performed on the UbcH10 silenced lung carcinoma cells.
As shown in Fig. 5C, the A459 and A549 cells transfec-
ted with siRNA against UbcH10 (siRNA UbcH10) were
retained in G1 phase (64.36% and 65.25%, respectively)
compared with the untransfected and control siRNA
transfected cells (siRNA C) (54.21% and 58.27%,
respectively).
Finally, we investigated the role of UbcH10 in cell
migration by performing a migration assay. The silenc-
ing of UbcH10 expression resulted in a reduction of
cell motility compared to control cells (Fig. 5D). As
we can see in Fig. 5D, the crystal violet staining of
wells (absorbance plotted in the histogram) carrying
A459 and A549 cells transfected with UbcH10 siRNA
was less intense (meaning that fewer cells had crossed
the membrane) compared to the staining of wells carry-
ing untransfected or non-silencing control transfected
cells (Fig. 5D).
Therefore, these results clearly demonstrate that the
block of UbcH10 expression markedly reduces the pro-
liferation and migration of lung cancer cells.4. Discussion
Today management of the patients aﬀected by lung
carcinomas requires a complex integration of clinical,
histological and molecular factors. The markers cur-
rently available are still far from yielding complete infor-
mations; recently, gene expression proﬁling has fostered
further investigation on novel biological markers of
potential future clinical use.25–30 Among those the
UbcH10 protein deserves investigation. Indeed, our pre-
vious studies have shown a signiﬁcant correlation
between UbcH10 overexpression and aggressive carci-
noma behaviour of ovarian, thyroid, breast and lym-
phoid neoplasms.13–15,18 A close relationship between
UbcH10 overexpression and poor tumour diﬀerentia-
tion has also been described in bladder, liver, colorectal
and brain tumours.9,16,17,31 Therefore, the aim of this
study was to evaluate whether UbcH10 also adds furthern in human lung carcinomas and its correlation with EGFR and p53
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Fig. 5. Deﬁnition of the role of UbcH10 in lung carcinoma cell proliferation and migration. (A) A459 and A549 cells were transfected with 120 nM
siRNA against UbcH10 and the relative control. Western blot was performed with lysate obtained from 24 h to 72 h after siRNA UbcH10
transfection. Total cell lysates were prepared and their concentration was measured using the Bradford assay. The expression of b-actin was used as
loading control protein. (B) A459 and A549 cells proliferation was determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,
MTT assay and absorbances were measured at 490 nm at diﬀerent times after transfection (0 h, 24 h, 48 h and 72 h). After transfection in 100 mm
plates, 5x103 cells were seeded in each well of the 96-well plate. Data were shown as means ± standard deviation (SD) of triplicate experiments. (C)
The distribution of cells in the diﬀerent phases of the cell cycle was evaluated by Fluorescence-activated cell sorting (FACS) analysis at 48 h after
transfection. 2x105 cells were stained with a solution containing 50 lg/ml propidium iodide and analysed for DNA content. (D) The migration of
A459 and A549 lung carcinoma cells was assessed 24 h after the silencing of UbcH10 compared to control cells. For migration assays, transwell
polycarbonate ﬁlters with 6.5 mm diameter and 8.0 lm pore size were used. 105 cells were seeded in the upper chamber and after 24 h incubation,
transwells were stained with crystal violet and absorbance was read at 595 nm.
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aﬀected by NSCLC.
For this study we took advantage of a TMA includ-
ing seventy-ﬁve lung carcinoma samples: this allowed to
simultaneously analyse a large number of samples
correlating the UbcH10 expression levels with a set of
clinicopathological and molecular parameters relative
to each patient. The evaluation of the UbcH10 mRNA
levels by qRT-PCR yielded similar results. Although
each technique was applied to a distinct set of samples,
our data suggest that there is a good correlation between
IHC and qRT-PCR. By the immunohistochemical anal-
ysis of this TMA we found that UbcH10 was overex-
pressed in all of the NSCLC analysed in comparison
with normal lung. UbcH10 levels were higher in SCC
and LCC compared to AD. Statistical analyses also
showed that the expression of UbcH10 in NSCLC was
moderately associated with proliferation index and, con-
sistently with the results previously reported in other
cancer types,13–16,32–34 was directly correlated with the
loss of tumour diﬀerentiation, since poor diﬀerentiated
carcinomas showed higher levels of UbcH10 with
respect to the well-diﬀerentiated ones. In agreement with
this result, higher levels of UbcH10 were found in the
NSCLC tumour samples expressing a mutated p53 pro-
tein that is well known to contribute to lung carcinoma
progression towards a less diﬀerentiated pheno-
type.23,24,35 Conversely, a lower UbcH10 expression
was observed in the presence of mutations in the EGFR
gene. This ﬁnding could have an important impact on
the therapy of NSCLC patients, since only patients
carrying EGFR mutations undergo treatment with
small-molecules inhibiting the EGFR tyrosine kinase.
Therefore, UbcH10 levels could represent, in a clinical
perspective, an additional indicator for the presence of
EGFR mutations, enforcing the criteria for choosing
the eligible patients undergoing anti-cancer treatments.
Functional studies demonstrated that the suppression
of UbcH10 expression reduced the proliferation rate of
two lung carcinoma cells, conﬁrming the important role
played by UbcH10 in lung carcinogenesis, likely due to
its ability to modulate the degradation of proteins such
as mitotic cyclins36 involved in cell cycle control. Consis-
tently, FACS analysis showed an accumulation of the
UbcH10-silenced lung carcinoma cells in the G1 phase
of the cell cycle.
Finally, we report that UbcH10 was also able to pos-
itively regulate the migration of lung carcinoma cells,
suggesting that UbcH10 might be involved, acting on
the ubiquitin–proteasome pathway, in the regulation
of the expression levels of proteins that modulate the
migration and invasiveness of cancer cells.
In conclusion, our results indicate a critical role of
UbcH10 in lung carcinogenesis. Further investigation is
required to evaluate the clinical role of UbcH10 detectionPlease cite this article in press as: Pallante P. et al., UbcH10 overexpressio
mutational status, Eur J Cancer (2012), http://dx.doi.org/10.1016/j.ejca.201as a tool to identify subset of NSCLC featuring speciﬁc
biological characteristics.
Conﬂict of interest statement
None declared.
Acknowledgements
This work was supported by grants from: AIRC
(IG 5346), Ministero dell’Universita` e della Ricerca
Scientiﬁca e Tecnologica –MIUR (PRIN2008), “Progetto
di Interesse strategico Invecchiamento (PNR-CNR Aging
Program) PNR-CNR 2012–2014” and Progetto PON01-
02782: “Nuove strategie nanotecnologiche per la messa a
punto di farmaci e presidi diagnostici diretti verso cellule
cancerose circolanti”.
We thank Mr. Mario Berardone for artwork.
Appendix A. Supplementary data
Supplementary data associated with this article can
be found, in the online version, at http://dx.doi.org/
10.1016/j.ejca.2012.09.033.
References
1. Walker S. Updates in non-small cell lung cancer. Clin J Oncol Nurs
2008;12:587–96.
2. Christiani DC. Genetic susceptibility to lung cancer. J Clin Oncol
2006;24:1651–2.
3. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers – a
diﬀerent disease. Nat Rev Cancer 2007;7:778–90.
4. Spira A, Ettinger DS. Multidisciplinary management of lung
cancer. N Engl J Med 2004;350:379–92.
5. Meuwissen R, Berns A. Mouse models for human lung cancer.
Genes Dev 2005;19:643–64.
6. Lowe SW, Sherr CJ. Tumor suppression by Ink4a–Arf: progress
and puzzles. Curr Opin Genet Dev 2003;13:77–83.
7. Sher YP, Chou CC, Chou RH, et al. Human kallikrein 8 protease
confers a favorable clinical outcome in non-small cell lung cancer
by suppressing tumor cell invasiveness. Cancer Res 2006;66:
11763–70.
8. Rossi G, Pelosi G, Graziano P, Barbareschi M, Papotti M. A
reevaluation of the clinical signiﬁcance of histological subtyping of
non–small-cell lung carcinoma: diagnostic algorithms in the era of
personalized treatments. Int J Surg Pathol 2009;17:206–18.
9. Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M,
Nakagawara A. UbcH10 is the cancer-related E2 ubiquitin-
conjugating enzyme. Cancer Res 2003;63:4167–73.
10. Lin Y, Hwang WC, Basavappa R. Structural and functional
analysis of the human mitotic-speciﬁc ubiquitin-conjugating
enzyme, UbcH10. J Biol Chem 2002;277:21913–21.
11. Rape M, Kirschner MW. Autonomous regulation of the ana-
phase-promoting complex couples mitosis to S-phase entry.
Nature 2004;432:588–95.
12. de Gramont A, Ganier O, Cohen-Fix O. Before and after the
spindle assembly checkpoint – an APC/C point of view. Cell Cycle
2006;5:2168–71.
13. Pallante P, Berlingieri MT, Troncone G, et al. UbcH10 overex-
pression may represent a marker of anaplastic thyroid carcinomas.
Br J Cancer 2005;93:464–71.n in human lung carcinomas and its correlation with EGFR and p53
2.09.033
10 P. Pallante et al. / European Journal of Cancer xxx (2012) xxx–xxx14. Berlingieri MT, Pallante P, Sboner A, et al. UbcH10 is overex-
pressed in malignant breast carcinomas. Eur J Cancer 2007;43:
2729–35.
15. Berlingieri MT, Pallante P, Guida M, et al. UbcH10 expression
may be a useful tool in the prognosis of ovarian carcinomas.
Oncogene 2007;26:2136–40.
16. Chen SM, Jiang CY, Wu JY, et al. RNA interference-mediated
silencing of UBCH10 gene inhibits colorectal cancer cell growth
in vitro and in vivo. Clin Exp Pharmacol Physiol 2010;37:525–9.
17. Donato G, Iofrida G, Lavano A, et al. Analysis of UbcH10
expression represents a useful tool for the diagnosis and therapy of
astrocytic tumors. Clin Neuropathol 2008;27:219–23.
18. Troncone G, Guerriero E, Pallante P, et al. UbcH10 expression in
human lymphomas. Histopathology 2009;54:731–40.
19. Angulo B, Suarez-Gauthier A, Lopez-Rios F, et al. Expression
signatures in lung cancer reveal a proﬁle for EGFR-mutant
tumours and identify selective PIK3CA overexpression by gene
ampliﬁcation. J Pathol 2008;214:347–56.
20. Travis WD, Brambilla E, Mu¨ller-Hermelink HK, Harris CC.
Pathology and genetics of tumours of lung, pleura, thymus and
heart. In: Travis WD, editor. World Health Organization Classi-
ﬁcation of Tumours. Lyon: IARC Press; 2004. p. 9–122.
21. Quintavalle C, Incoronato M, Puca L, et al. C-FLIPL enhances
anti-apoptotic Akt functions by modulation of Gsk3beta activity.
Cell Death Diﬀer 2010;17:1908–16.
22. Quintavalle C, Garofalo M, Zanca C, et al. MiR-221/222
overexpression in human glioblastoma increases invasiveness by
targeting the protein phosphate PTPmu. Oncogene 2011;31:
858–68.
23. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco
exposure, and lung cancer. Hum Mutat 2003;21:229–39.
24. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung
cancer. Annu Rev Med 2003;54:73–87.
25. Beer DG, Kardia SL, Huang CC, et al. Gene-expression proﬁles
predict survival of patients with lung adenocarcinoma. Nat Med
2002;8:816–24.Please cite this article in press as: Pallante P. et al., UbcH10 overexpressio
mutational status, Eur J Cancer (2012), http://dx.doi.org/10.1016/j.ejca.20126. Granville CA, Dennis PA. An overview of lung cancer genomics
and proteomics. Am J Respir Cell Mol Biol 2005;32:169–76.
27. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer –
molecular and clinical predictors of outcome. N Engl J Med
2005;353:133–44.
28. Wigle DA, Jurisica I, Radulovich N, et al. Molecular proﬁling of
non-small cell lung cancer and correlation with disease-free
survival. Cancer Res 2002;62:3005–8.
29. Endoh H, Tomida S, Yatabe Y, et al. Prognostic model of
pulmonary adenocarcinoma by expression proﬁling of eight genes
as determined by quantitative real-time reverse transcriptase
polymerase chain reaction. J Clin Oncol 2004;22:811–9.
30. Hoheisel JD. Microarray technology: beyond transcript proﬁling
and genotype analysis. Nat Rev Genet 2006;7:200–10.
31. Han SS, Liu QG, Yao YM, et al. UbcH10 expression in
hepatocellular carcinoma and its clinicopathological signiﬁcance.
Nan Fang Yi Ke Da Xue Xue Bao 2011;31:280–4.
32. Fujita T, Ikeda H, Kawasaki K, et al. Clinicopathological
relevance of UbcH10 in breast cancer. Cancer Sci 2009;100:
238–48.
33. Fujita T, Ikeda H, Taira N, Hatoh S, Naito M, Doihara H.
Overexpression of UbcH10 alternates the cell cycle proﬁle and
accelerate the tumor proliferation in colon cancer. BMC Cancer
2009;9:87.
34. Troncone G, Volante M, Iaccarino A, et al. Cyclin D1 and D3
overexpression predicts malignant behavior in thyroid ﬁne-needle
aspirates suspicious for Hurthle cell neoplasms. Cancer Cytopathol
2009;117:522–9.
35. Feldser DM, Kostova KK, Winslow MM, et al. Stage-speciﬁc
sensitivity to p53 restoration during lung cancer progression.
Nature 2010;468:572–5.
36. Lukas J, Bartek J. Cell division: the heart of the cycle. Nature
2004;432:564–7.n in human lung carcinomas and its correlation with EGFR and p53
2.09.033
